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ABSTRACT 
It is proposed that Ionic Liquids (ILs) offer a new opportunity for exploration into a novel 
medium for processing Active Pharmaceutical Ingredients (API), particularly with respect to 
habit control and polymorphic form. It is possible that due to the highly functional nature of 
these materials that they could offer a new route to manipulation of physical form, drug 
substance version and crystal structure during particle formation and growth. It is this basic 
hypothesis which the project aims to test. 
A review of relevant literature relating to ionic liquids properties, commercial applications 
and current research has been summarised together with background into fundamental 
crystallisation theory.  
Methods to establish the solubility of API in ILs was determined by using the common APIs 
paracetamol and ibuprofen in two common ionic liquids [bmim][PF6] and [hmim][PF6] and 
the data are fitted using two established solubility modelling equations. Crystallisations 
using thermal methods were employed at laboratory scale and the physical properties of the 
resultant powders were analysed and compared to commonly encountered crystal forms. 
The crystallisation work was extended by selecting a test set of ILs for further screening 
work. Practical issues in working with this medium were encountered during development 
and have been documented together with possible solutions. 
It was shown that, for the systems studied, good solubility can be achieved and that the data 
can be modelled successfully using widely used models. For all the APIs studied in this work, 
cooling crystallisations were successfully used to crystallise material for characterisation. For 
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paracetamol it was found that the morphology of the crystals could be manipulated, 
producing in some cases, habits not reported for conventional organic solvent crystallisation. 
This was achieved through changing both the IL used and the saturation of the system whilst 
in all cases retaining the most stable polymorph. The same range of particle modification 
could not be repeated for ibuprofen whose morphology and form remained constant 
throughout. Studies on flufenamic acid showed that metastable forms can be isolated 
through changes in the IL and method employed. In general crystallisation from ILs followed 
the same fundamental principles as for other media. However there is potential for an ILs to 
be ‘designed’ for a given API but greater understanding of the interactions between IL and 
solute are required first. 
Properties such as increased solvation power, thermal stability, liquidus range and low 
vapour pressure bring a number of advantages when designing industrial crystallisations. 
However ILs also have a number of disadvantages including phase separation problems. 
These may be solved through deploying other strategies such as use of co-solvents or 
potentially non-routine crystallisation methods such as Supercritical Fluid (SCF) 
crystallisation. 
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CHAPTER 1: INTRODUCTION 
The mechanisms which govern the biopharmaceutical performance of an Active 
Pharmaceutical Ingredient (API) such as solubility, chemical and physical stability are 
intrinsically linked to the physical form of the API and can also impact the manufacturability 
of drug products. The final crystallisation of an API is therefore fundamental in delivering a 
safe, efficacious drug product which can be manufactured at commercial volumes. 
Predominately APIs are purified and isolated from chemical synthetic process as powders by 
crystallisation from organic or aqueous based solvents or mixtures thereof. The final 
crystallisation step is critical to ensure that the API produced is of a high purity, the correct 
polymorphic form and the particle habit and size is conducive for isolation and subsequent 
downstream processing. The range of solvents available for these processes is limited and 
therefore the properties of the solvent are not always ideally suited to a given process. This 
can lead to the use of large quantities of volatile solvents which have a significant impact on 
both the process cost and environmental impact of such processes. 
Is has been proposed that Ionic Liquids (ILs) may offer a new opportunity as novel media for 
processing API, particularly with respect to habit control and polymorphic form. ILs are 
unique solvents as it is possible to manipulate their properties by altering the cation, anion 
or substituent side chains. This means that they have the potential to be designed for a 
specific process or API. Common characteristics such as good solvation power, wide liquidus 
range, thermal stability and low vapour pressures means that they may also offer significant 
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advantages to reduce both the cost and environmental impact of pharmaceutical 
crystallisation processes.  
The objectives of this work were firstly to examine the current literature and summarise: the 
background to ionic liquids, the current state of the art in crystallisation from ILs and gaps in 
current knowledge. Secondly, using well characterised ionic liquids and APIs to assess the 
practical implications of using ILs as crystallisation media by conducting laboratory scale 
experiments and where possible establish whether the additional molecular functionality of 
ILs can be exploited to modify physical form and beyond that whether a rationale can be 
developed to describe in qualitative or quantitative terms the underlying mechanisms for 
crystal growth and form modification. 
Overall the thesis aims to help establish what may be practically possible with this novel 
media and whether they can be used to control the physical form of API.  
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CHAPTER 2: LITERATURE REVIEW 
2.1 Definition of Ionic Liquid and Brief History 
Ionic liquids (ILs) are liquids predominately composed of ions, they contain at least one 
organic cation and one anion and by definition are liquids at less than 100 °C (with many 
being liquids at room temperature). It is this low melting point, relative to molten salts, that 
has opened up the field to a wide range of potential applications.  
As with many research areas it is difficult to define an exact date by which it is generally 
accepted that the field started. Wilkes (2002) suggests that the history of ILs can be traced 
back to the mid-19th century when chemists noted a ‘red oil’ produced from a side product 
of a Friedel-Crafts reaction. This ‘red oil’ was not of interest at the time but has since been 
proposed to be an ionic liquid based on a heptachlorodialuminate salt. However it wasn’t 
until 1914 when the synthesis and physical properties of ethyl ammonium nitrate (EAN), 
which has a melting point of 12 °C, was documented by Walden (1914); many believe this 
marks the true start of IL research (Plechkova and Seddon, 2008). 
Fundamental research into ILs began in earnest throughout the 1960s and 1970s when 
chloroaluminate salts for use in thermal batteries was investigated by the US Air Force 
Academy (US Patent 4122245, 1978) in collaboration with groups at the Colorado State 
University (Koch et al, 1976 and Gale et al, 1978). However many of the ILs discovered in this 
era were found to have melting points in excess of 40 °C and suffered from hydrolysis issues; 
this led to the search for more stable and lower melting ILs.  
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In the 1980s ILs based on imidazolium cations were investigated and published (Fannin et al, 
1984). Using this cation a series of ILs were produced that were liquids at or around room 
temperature and it is this cation that the majority of research still carried out with. However 
a major drawback of the ILs used in this research was that the anions, which were based on 
chloroaluminate, were found to be reactive with water.  
Synthesis of the imidazolium based cation was extended from chloroaluminates to ions such 
as tetrafluoroborate, hexafluorophosphate, nitrate, sulphate and acetate  (Zaworotko and 
Wilkes, 1992) which were found to be stable with water (at ambient conditions).  
The discovery of these air and water stable ILs provided the spark for research into 
numerous fields over the last two decades, as can be seen from the number of articles that 
have been published since 1980 as shown in Figure 2.1. 
 
Figure 2.1: Ionic Liquid Publications 1992 to 2013 
Although many areas of research were initiated using these newly found stable ILs the 
largest area of focus in the 1990s and early 2000s was their use in chemical reactions. 
Specifically, it was shown that they could be used as media in a large range of chemical 
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reactions while providing reaction rates that were either comparable or better than 
conventional organic solvents (Welton, 1999 and Seddon, 1996). Reactions studied include 
isomerisations, alkylations, Diels-Alder reactions, hydrogenations and Heck and Suzuki 
coupling reactions.  
This work greatly expanded the demand for ILs and as such there are now a number of 
commercial suppliers providing an ever expanding range of ILs ready for use. This, coupled 
with the ever increasing drive to find ILs that are both chemically and biologically inert, 
whilst remaining liquid at room temperature, has now made their use in the pharmaceutical 
arena possible.  
This brief development history brings ILs into the current age of research. Their use in the 
pharmaceutical industry is the focus of this thesis and a greater commentary of the current 
research in this area is detailed in later sections. 
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2.2 Properties 
The number of potential number of ILs consisting of a single cation and anion (although 
more complex examples do exist) gives in the region of 106 possible combinations. To put 
this into context there are just approximately 600 conventional molecular solvents 
(Plechkova and Seddon, 2008). It is this potential choice that has facilitated much of the 
investigation into ILs as many researchers look to them as ‘designer solvents’ whose 
properties could potentially be tailored and refined for a specific process.  
Given the large number of possible ILs it is not appropriate to generalise the properties, as 
such a large number of possible combinations means that exceptions to general ‘rules of 
thumb’ can almost always be found. Up to date physical properties of many ILs can be found 
on Ionic Liquids Database - ILThermo (v2.0) (2014) and there are also a number of reviews 
documenting the properties of many commonly used ILs (Weingarten, 2008, Zhang et al, 
2006, Domanska, 2006 and Fredlake et al 2004). 
While it is beyond the scope of this work to outline the full range of possible 
physicochemical properties available, a summary of properties of common ILs that are most 
pertinent to this work are described in Table 2.1.  To highlight some of the major differences 
the properties are compared with three of the most commonly used organic solvents in the 
manufacture of APIs at GlaxoSmithKline (Constable et al, 2007). 
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 Ionic Liquids Organic Solvent 
Property 
[bmim] 
[PF6] 
[bmim] 
[BF4] 
[bmim]  
[C2F6NO4S2] 
MeOH IPA EtOAc 
Molar Mass            
g mol-1 
284.2 226 419.4 32.0 60.1 88.1 
Melting Point  K 283 202 272 176 184 190 
Liquidus Range K 339 474 440 162 172 160 
Relative Polarity 0.667 0.673 0.664 0.76 0.57 0.23 
Density at 298 K 
Kg.m-3 
1350 1260 1430 792 786 897 
Viscosity at 293 K 
 Pa s (103) 
450 154 69 0.59 1.96 0.426 
Table 2.1: Comparison of Sub-set of ILs and Organic Solvents 
The small subset of ILs and organic solvents shown here highlights some of the major 
differences between ILs and organic solvents. These properties are further analysed in the 
sections below. 
2.2.1 Structure 
Commercially available ILs are based on a relatively small number of core structures shown 
in Figures 2.2 and 2.3. The cations are generally single charged species where the charge is 
distributed across the entire structure avoiding strong coulomb interactions. They are large 
bulky asymmetric structures that prevent packing of the unit cell and hence crystallisation. 
The most widely researched ILs are based on the imidazolium cation as they are relatively 
easy to produce and are perceived to have good physical properties. Other commercially 
available cations are based on ammonium, phosphonium, pyridinium, pyrrolidinium and 
sulfonium.  
The substituents on the cation are typically alkyl chains but can contain a variety of other 
functional groups such as fluroalkyl, alkeny and methoxy. Increasing the length of an alkyl 
chain tends to decrease water solubility by increasing the hydrophobicity of the cation. 
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Figure 2.2: Common Cation Structures; Imidazolium, Ammonium, Phosphonium, 
Pyridinium, Pyrrolidinium and Sulfonium 
 
The choice of anion also influences the chemical and physical properties of an ionic liquid. 
For example ionic liquids based on the imidazolium cation can be made to be totally miscible 
or immiscible with water through careful choice of anion (Rogers and Seddon, 2002). 
, ,  
 
Figure 2.3: Common Anion Structures; Alkylsulfate, Hexafluorophosphate, 
Tetrafluoroborate, Acetate, Bis(trifluoromethylsulfonyl)imide, Halide 
2.2.2 Melting Point and Liquidus Range 
When looking to use ILs as crystallisation solvents it is key that the IL remains as a liquid 
during the separation of the solid product. While ILs are defined as having a melting point 
less than 100 °C melting temperatures at or below room temperature are more desirable 
from a processing perspective. All three major components of the IL (cation, side chains and 
anion) will have an impact on the melting point of an IL. 
Large cations and increased asymmetric substitution results in a reduction of the melting 
point. Short side chains are more likely to form crystalline phases with comparatively high 
melting points whereas medium sized tend to have low melting points with a large liquidus 
range. The melting point of ILs with long side chains can be complicated as they can result in 
complex phase diagrams and are dependent on the anion and its ability to hydrogen bond. 
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Increasing the anion size has the impact of decreasing the Coloumb interactions in the 
crystal lattice, decreasing the melting point. For example the melting point of ILs containing 
halides tends to be much higher than ILs containing hexafluorophosphate or 
bis(trifluoromethylsulfonyl)imides (Zhang, 2006). 
The melting points of ILs are considerably higher than organic solvents as the examples in 
Table 2.1 show. This will restrict the number of ILs that could be considered for use via 
conventional crystallisation methods and may be one of the drawbacks of ILs that has 
restricted their use as pharmaceutical solvents. 
The temperature range over which ILs remain in the liquid state (liquidus range) are far 
superior to conventional organic solvents. Typically the liquidus range is the difference 
between the boiling and melting points, however as ILs have no discernible vapour pressure 
the liquidus range is determined by the difference between the decomposition temperature 
(as measured by Thermal Gravimetric Analysis, TGA) and the melting temperature. 
Liquidus ranges in the region of 300 to 500 K are commonly found for ILs whereas typical 
liquidus range for organic solvent is typically in the region of 100 to 200 K. So while the 
melting temperature of many ILs may preclude them from conventional crystallisation 
methods the superior liquidus range offers an opportunity to work at a much greater range 
of temperatures than possible using conventional solvent systems. 
2.2.3 Vapour Pressure and Thermal Stability 
While for most applications ILs could be considered to have negligible vapour pressures it is 
false to claim that ILs have no vapour pressure as in some cases this has been measured 
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(Esperanca et al, 2010) and some ILs have even been designed to undergo distillation (Earle, 
2006).  
The thermal stability of ionic liquids is limited by the strength of their heteroatom-carbon 
and their heteroatom-hydrogen bonds. It has been reported that ILs can be stable up to 
temperatures of 700 K. However such high temperatures can only be tolerated by ionic 
liquids for a short period as long time exposure at high temperatures leads to decomposition 
(Kosmulski et al, 2004). 
The low vapour pressure means that ILs are not susceptible to evaporation which helps 
reduce emissions and also offers the possibility that ILs could be used at temperatures never 
possible using conventional solvents without the need for extensive changes to 
infrastructure. This could make ILs very efficient solvents for chemical processes such as API 
manufacture and crystallisation.  
2.2.4 Polarity 
Commonly used to describe the solvation capability of a solvent, polarity is important when 
considering a solvent for a particular application. For molecular solvents the relative 
dielectric permittivity or static dielectric constant, εs, can be measured directly. However 
because direct measurement requires a non-conducting medium the dielectric constant of 
ILs needs to be determined by measuring the frequency dependent dielectric permittivity 
and extrapolating to zero. Using this method ILs can be classified as moderately polar 
solvents. However it should be noted that generally the εs values tend to be lower than for 
other methods. 
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Another common empirical method used to measure the polarity of ILs is the use of 
solvatochromic or fluorescent dyes, where the change in absorption when the dye comes 
into contact with media of different polarity. One of the most common scales is the 
Dimroth–Reichardt ET(30) scale (Reichardt, 2005), based on the N-(4-oxidophenyl) 
pyridinium dye, where the difference in solvation of the dipolar zwitterionic ground state 
compared to the less polar first state is detected by a shift in λmax from 453nm to 810nm. A 
polarity scale, ET(30), is used to scale solvent polarity. Increasing the value of ET(30) leads to 
a  polarity increase; however values are often normalised to give a parameter ET. Solvents 
are normalised to values between N = 0.0 (tetramethylsilane) and 1.0 (water). 
For the examples used in this work shown in Table 2.1 the ILs are within the range 0.664 to 
0.673 which would indicate that they have a similar polarity to methanol. The anion has 
been found to have little influence on the ET values (Muldoon, 2001), hence the values 
shown for the ILs in Table 2.1 are very similar to each other. In the same study it was found 
the alkyl chain length also has little impact with a small decrease detected for increasing 
chain length, a similar effect also observed in short chain alcohols. The biggest influence is 
therefore from the cation. ET values are known to be strongly influenced by the ability of a 
solvent to act as a hydrogen bond donor and it is this property of the cation that influences 
the polarity value for this dye. 
 It is unclear whether the concepts for rationalising the polarity of ILs this way are suitable 
given the complex nature of the bonding in these media. Further work is needed to 
understand these complex systems to determine the interplay between different bonding in 
ILs and how they interact with solutes. 
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2.2.5 Viscosity and Density 
The viscosity of an IL is determined by the ability to form hydrogen bonds and Van der Waals 
interactions. ILs have viscosities that are orders of magnitude more viscous than most 
conventional solvents. Both the cation and anion can have significant effect, the magnitude 
of which is particular to the bonding ability of a given ion. For example, for some of the 
anions used in this work in a homologous series of cations, as shown in Table 2.1, the 
following trend occurs: [(CF3SO2)2N
-] < [BF4] < [PF6]. The impact of alkyl chain length is less 
pronounced than changing either of the ions but increasing alkyl chain length will result in an 
increase in viscosity. The viscosities of ILs are also known to be highly temperature 
dependent and they can be extremely viscous at low temperatures. 
In general ionic liquids have densities greater than water and organic solvents, with densities 
ranging from 1260 kg.m-3 to 1430 kg.m-3 for the examples shown in Table 2.1; as the side 
chain of the ionic liquid increases the density decreases. The densities are also affected by 
anion type. 
The high viscosities and densities of ILs and their high temperature dependence compared to 
more conventional solvents would mean that careful attention would need to be given to 
the mixing conditions and any impact on the filtration processes. 
2.3 Safety, Environmental, Regulatory and Cost 
For any new chemical entity that is being considered for a pharmaceutical process it is 
important to also consider the process safety, environmental impact, regulatory implications 
and costs. A comparison of some of the indicators used to assess such details are 
summarised for the same solvents previously in Table 2.2.  
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 Ionic Liquids Organic Solvent 
Property 
[bmim] 
[PF6] 
[bmim] 
[BF4] 
[bmim]  
[C2F6NO4S2] 
MeOH IPA EtOAc 
Hazard Notations 
(Hazard Category) 
Skin Irritant (SI), Skin Corrosion 
(SC), Eye Irritant (EI), Serious Eye 
Damage(SED), Specific Organ 
Toxicity (SOT), Acute Toxicity 
(AT), Flammable Liquid (FL) 
SI (2) 
EI (2A) 
SOT (3) 
AT (3),  
SI (2) 
EI (2A),  
AT (3) 
SC (1) 
 SED (1)  
SOT (2) 
 
FL (2) 
AT (3) 
SOT (1) 
FL (2) 
EI (2) 
SOT (3) 
FL (2) 
EI (2) 
SOT (3) 
Environmental 
Notations 
AQT = Acute Aquatic Toxicity 
ST = Slightly Toxicity 
AQT (2) AQT (2) AQT(2) ST n/a n/a 
Degradation  
Not Readily Biodegradable (NRB) 
Readily Biodegradable (RB) 
NRB NRB NRB RB RB RB 
Safety Marker 
LD 50 (rat) in mg.kg-1 
300 - 500  > 50 - < 300 300 5630 5050 5620 
Cost £/kg (July 2014) 448.00 486.84 1506.00 0.58 1.18 1.14 
Table 2.2: Comparison of Safety, Environmental, Toxicity and Cost 
2.3.1 Safety 
The flammability of organic solvents means that significant controls are required to ensure 
safe handling, dispensing and chemical plant / equipment design. The low or negligible 
vapour pressure could bring advantages on how solvents are safely controlled in chemical 
processes by significantly reducing the flammability risk. 
Despite these clear advantages the safety of ILs needs careful consideration, especially in 
chemical synthesis processes as ILs can be reactive (Chowdhury et al, 2007), so the 
compatibility with reaction mixtures would need to be assessed on a case by case basis. 
Many of the ILs have specific safety notations, as the examples in Table 2.2 show, which may 
require the user to have a greater level of protective equipment in order to prevent 
unexpected exposure.  
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The degradation products also need to be carefully monitored. For example it is known that 
hydrogen fluoride is formed when water is present in a number of fluorine containing ILs 
such as the commonly used PF6 and BF4 anions (Huddleston et al, 2001). 
2.3.2 Environmental 
One of the many perceived advantages of ILs is that they are ‘green’ solvents. This is 
primarily based on the reduction of volatile emissions that replacing organic solvents could 
bring (MacFarlane and Sneddon, 2007). 
Any environmental impact needs to be considered as a whole rather than just the impact on 
emissions. While much research has gone on into the production of ILs and their 
applications, measurements of potential environmental impact is still to be fully detailed. It 
was recognised within the scientific community that a systematic approach to measuring, 
reporting and where possible predicting environmental impact was required. The Centre for 
Environmental Research and Sustainable Technology located in Bremen has now measured 
the environmental toxicology of over 300 ILs and their data, together with other literature 
data, provides a useful resource for evaluating the environmental toxicology of ILs (Thuy 
Pharm, 2010). 
Their studies have shown that the biggest influence on the ecotoxicity has been found to 
come from the alkyl side chains, while generally the cation itself seems to have little 
influence (although noted that some pyridium and quinolinium head groups are found to be 
exceptions to this).  
The environmental toxicity can be altered by changing the hydrophobicity of the IL, for 
example reducing the alkyl chain length or introducing polar functional groups can improve 
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the environmental toxicity. Most anions do not display significant environmental toxicity. 
The exceptions to this are hydrophobic anions which tend to be fluorinated which gives 
them specific environmental toxicity as shown in Table 2.2. As the use of ILs becomes wide 
spread there is increasing focus on what their long term environmental toxicity may be. 
Good reviews on the subject have been written by Thuy Pham et al (2010), Romero et al 
(2008) Frade and Afonso (2010). 
Currently not much is known about the biodegradation of ILs. However some general rules 
are known. Cations based on pyridinium exhibit higher degrees of biodegradation than 
imidazolium based ILs. Also the larger the side chain, the better the biodegradation (trade 
off between biodegradability and environmental toxicity). For the anions, alkyl sulphates and 
salts of organic acids (e.g. acetate or lactate) are recommended, while fluorine containing ILs 
should be avoided. 
2.3.3 Regulatory Status 
Regarding regulatory status of ILs no guidance has yet been published from the relevant 
authorities. If ILs are to be used in the manufacture of APIs then more extensive research 
and justification for use will be required. Guidelines in place for conventional solvents 
require low values of solvent to be present and unless the ILs themselves are designed to be 
tolerable it should be expected that equally strict regulations would exist for these solvents. 
The tolerability of ILs would need to be determined in safety studies to ensure that there 
would be no adverse toxicological risks passed onto patients if trace levels of IL remained. 
This would also require the development of sufficient analytical methods in order to 
determine trace levels of IL.  
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2.3.4 Cost 
Currently ILs can be considered as niche solvents and the cost reflects this status although 
the purification of ILs can be problematic and they are likely to always have a higher initial 
cost compared to commonly used organic solvents. This cost could be offset if the IL can be 
sufficiently recycled from batch to batch; in this case over the lifecycle of the IL the increased 
cost may be negligible. The range of possible ILs means that it is not commercially viable to 
make large quantities for general purchasing. The approach taken by companies like BASF is 
to supply a limited range and once a suitable IL is identified a bespoke product can be 
negotiated. This would allow bespoke specifications to be determined to control attributes 
such as purity, by-products, halogen content, colour, viscosity etc. If the process required 
large volumes then this would also drive the cost of the IL down. The cost to manufacture 
API using current solvents provides by far the highest impact to the cost of the drug product. 
If a proposed process is to use an IL it must also be economically viable and not significantly 
impact the cost of goods. 
Overall it is clear that ILs have some unique properties that make them stand out from 
conventional organic solvents as broadly summarised in Table 2.3. While some of these 
properties may provide technical solutions to a given problem, in order for successful 
implementation much more work is needed to understand the lifecycle impact of this 
potential new medium. 
Property Organic Solvent Ionic Liquid 
Number of Solvents > 103 > 106 
Flammability Usually Flammable Usually Non-Flammable 
Operating Range circa. 100 °C circa. 300 °C 
Viscosity Low High 
Safety and Environment Well understood Emerging Data 
Cost Normally Cheap Expensive 
Table 2.3: Comparison of Organic Solvent and ILs 
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2.4 Applications 
The rise in published articles on ILs in the last decade gives an indication as to the breadth of 
research that ILs currently spans. While they have found applications in diverse areas of 
research the sections below have concentrated on commercial applications and research 
that is focused on their use either in the delivery of APIs or as a medium for particle 
formation. 
2.4.1 Industrial Applications 
Chemical Processing 
It is claimed (Maase and Massonne, 2005) that the first industrial application using ILs was 
the BASIL (Biphasic Acid Scavenging utilizing Ionic Liquids) process by BASF™. The process is 
used for the production of a generic photo-initiator. Using 1-methylimidazole as an acid 
scavenger an ionic liquid is formed, which is then separated and used for further reaction 
steps. The process has been in routine production since 2002 producing ILs on a multi-ton 
scale.  Comparing to the previously used process the yield was increased from 50% to 98% 
allowing the process to be conducted using a much smaller reactor.  
While the BASIL process was the first self proclaimed commercialised process, in fact the 
Eastman Chemical Company had been running a process involving an isomerisation that 
required a phosphonium based IL to act as a Lewis basic media. The process run by the Texas 
Eastman Division in a plant with a 1400 metric ton capacity operated from December 1996 
through to 2004. The process was terminated due to decline in requirement for the product. 
(Plechkova and Seddon, 2008) 
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Other noteable processes that may be future commercial processes include: cellulose 
processing which was developed at University of Alabama by a group headed by Robin 
Rogers (Swatloski et al, 2002) and has now been licensed by BASF. Cellulose is the earth’s 
most abundant natural organic resource, an important bio-renewable resource and the 
excellent solvation properties of ILs mean that dissolution of this biomass can be achieved 
and utilised for subsequent processing.  
Petrochemical Industry 
The petrochemical companies such as BP, ExxonMobil, Chevron have invested heavily in a 
number of areas including refining, extraction, waste processing and emulsification 
(Plechkova and Seddon, 2008). While they have been very active in the field it is not clear 
what the current stage of development these processes is. However, currently the largest 
commercial process is run by a petrochemical company. The PetroChina process which is a 
sulphuric acid alkylation process named Ionikylation produced 65,000 tonnes of product per 
year. The process was retrofitted to the existing plant and has improved the process yield 
such that an increase in the process capacity of 248 tonnes a day (40%) was achieved. Also in 
the petrochemical arena the Institut Français du Petrole (IFP) patented a process called 
Difasol, which is operated by a company called Axens. The process, which uses 
chloroaluminate ILs as solvents for nickel catalysed dimerisation reactions, has been shown 
to have a number of improvements over the existing Dimersol process such as improving 
selectivity, yield, catalyst use and reduced reactor size. 
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Other Industries 
Electroplating processes such as BASF’s aluminium plating process or the chromium plating 
process from Scionix have also been developed as commercial processes for electropolishing 
of stainless steel, meanwhile Degussa have used ionic liquids to improve the appearance and 
drying properties of their paints under the name TEGO Disps and the Pliolite range.  
Summary 
The above applications demonstrate that ILs can be and have been developed into viable 
commercial processes. The chemical processing and petrochemical industries have shown 
the greatest success in developing commercial processes. Many of the largest processes 
have been developed and implemented before the recent upsurge in IL research. As more 
and more applications are investigated the number of commercial applications is expected 
to rise and diversify into other industrial sectors. 
2.4.2 Pharmaceutical Based Research 
There has been much focus on the chemistry involved in the synthesis of APIs and good 
reviews in this field have been published already (Welton, 1999). The literature reviewed in 
the section below has been targeted to cover the areas relevant to the use of ILs in the 
pharmaceutical industry and particle engineering of materials using ionic liquids. 
One emerging area of focus for ILs is their application in the production and delivery of 
Active Pharmaceutical Ingredients (API). The strategies employed can be broadly split into 
two approaches; use of ILs as drug delivery vehicles to dissolve and deliver API and the 
development of ILs that are designed to be the API. 
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Solubility of API in ILs 
While their use in green chemical processes was of interest in the last ten years it is their 
unique solvation properties that have re-ignited interest in the industry. Research groups 
have shown (Mizuuchi et al, 2008) that the solubility of poorly water soluble drugs such as 
albendazole and danazol could be significantly increased (more than 10,000 times in the 
case of albendazole). The ILs used in this study were hydrophobic and immiscible in water; 
however it was demonstrated that the miscibility could be improved through addition of a 
second more miscible IL.  
Recently a number of solubility studies have been published. For example Forte et al (2012) 
measured the solubility of anti-tubercular drugs in ILs based on the imidazolium cation and 
bis(trifluoromethylsulfonyl)amide and trifluoromethanesulfonate anions. They measured the 
solid-liquid equilibrium using thermal techniques and used six different correlation 
equations to provide a fit for the data. The work shows that, in terms of solubility, ILs 
provide a viable alternative to molecular solvents for pharmaceutical processing. 
Interestingly the correlation equations that are well established for molecular solvents was 
able to provide a reasonable fit to the experimental data. The solvation mechanisms 
involved in ILs are still largely unknown so as data continues to emerge relating to 
established correlations which may help to identify similarities and differences between ILs 
and molecular solvents as more data are published. 
A feature from the published solubility work is that compounds that exhibit poor solubility in 
organic solvents can often be solubilised using ILs.  The reason for the increased solvation 
properties in ILs has been debated in a number of journals. Using Flory-Huggins theory, 
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Areov et al (2006) proposed that the extra solvation power is due to the repulsive force 
created between the shells of the anion and cation. The only way to reduce this repulsive 
force is to dissolve the solute molecules to help shield this effect. 
ILs as Drug Delivery Systems 
The ability to dissolve poorly soluble API has been exploited by a number of authors, namely 
Jaitely et al (2008) who was one of the first to publish on the use of ILs in drug delivery, 
investigating the use of the hexafluorophosphate anion with imidazolium cation with 
differing alkyl chains. They showed that controlled release of solute into the aqueous phase 
was achieved and that the release profile could be manipulated by changing the alkyl chain 
length and hence the hydrophobicity of the IL. This impacts both the solubility of the solute 
but also the hydrophobicity of the IL and hence the partition co-efficient and release of the 
drug from the IL into the aqueous phase. 
This approach has been taken forward by other authors such as Moniruzzaman (2010) who 
developed a microemulsion process to form thermodynamically stable emulsions that were 
found to have spherical micelles in the range of 8-34 nm.  
The use of ILs as a drug delivery vehicle to deliver poorly soluble API has been investigated 
by a number of groups. For instance Williams et al (2014) have showed, through careful 
targeting of the IL, that the solubility of danazol and itraconazole could be significantly 
enhanced with a more prolonged exposure when compared to a lipid formulation. 
Both of the above authors highlight that one of the great unknowns of these approaches is 
the toxicity of the IL being used to deliver the API. Both completed toxicity tests and showed 
that no significant toxicity was observed. While these results are encouraging much more 
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work is required to assess both the toxicity but also the persistence and the clearance of ILs 
in-vivo. Until this is addressed questions will always be raised when direct administration of 
ILs in formulations is proposed. 
ILs as Active Pharmaceutical Ingredients 
The concept of using ILs as the API was published by Hough et al (2007) where they propose 
that pure liquid salt forms of APIs should be considered and may be useful for overcoming 
commonly encountered problems in the solid form such as polymorphism, solubility and 
bioavailability. The concept was demonstrated by producing IL-APIs of Ranitidine 
Hydrochloride (Histamine H2-receptor, active ingredient in Zantac), lidocaine hydrochloride 
(pain reliever that is commonly delivered topically) and ibuprofen (common anti-
inflammatory). Lidocaine (cation) was paired with docusate (anion) to produce lidocaine 
docusate which formed a clear colourless gel with a measured glass transition of 244 K. 
Biological testing was completed on this via topical application and it was found that release 
of the API was observed. However, compared to the conventional formulation the release 
was slower, indicating the mechanism of release was different, but this opens up the 
possibility of controlled release formulations. This initial work has been followed up with a 
position paper from Stoimenovski et al (2010) and more recently a review by Shamshina et 
al (2013). 
There are a number of potential advantages that this approach could bring: firstly the 
authors highlight that as the material remains in liquid form no control over the 
polymorphism would be required, secondly, through careful selection of the counter ion it 
may be possible to control the solubility either to enhance it or to act as a controlled release 
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mechanism, thirdly it has been it has been demonstrated that it may be feasible to produce 
a dual active API where both ions are pharmaceutically active. This provides the possibility of 
delivering combination products in a manner where both actives would dissolve at exactly 
the same time as the each other (this is not true of co-administered salts).  
There are a number of considerations that need to be researched before any of the above 
benefits could be realised. Firstly the pharmaceutical industry has historically always worked 
with solids and the regulations which govern the development and manufacture of 
pharmaceuticals have been developed accordingly, so if ILs were to be considered, control 
strategies would need to be carefully considered from both the pharmaceutical and the 
regulatory authorities. The delivery systems used to deliver these liquid APIs would also 
need to be considered, as current delivery technologies (such as softgel capsules) may not 
be compatible with these new materials. The same can also be said for the filling systems 
used in the manufacture; current infrastructure may not be viable, requiring significant 
investment from companies if the technology is to be implemented. 
Published literature in this area also points out that little or nothing is known about the 
toxicological effects of the majority of commonly used ions, which would require safety 
studies to be conducted. The point is valid; however this should not preclude IL-APIs being 
investigated, as any API under development would be treated as a new chemical entity and 
would be subject to both safety and efficacy testing during its development. However many 
of the commonly used counter ions that have been used in IL research to date do have high 
toxicity and would not be suitable as pharmaceutical ingredients, this limitation will limit the 
flexibility of this approach. 
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Like conventional API salts, ILs which have been crystallised have been shown to 
demonstrate polymorphism. Cherukuvada and Nangia (2012) formed three polymorphs of 
the dibenzoate salt of the anti-tubercular drug ethambutol. However if the IL can be shown 
to remain in a liquid state throughout its lifecycle, then this strategy could be used to avoid 
the need to control polymorphic forms of API.  
Crystallisation Using ILs 
While the use of ILs for drug release or as the API may be some way off, given the present 
hurdles, they have undoubtedly been shown to be useful media for chemical reactions and 
for solubilising otherwise poorly soluble compounds, which suggests that ILs may be useful 
crystallisation media. 
Given the vast amount of research that is conducted in ILs there are relatively few 
publications in this area. Many crystallisation practitioners would argue that ILs are not 
conducive to crystallisation. There are a number of reasons why this would be considered to 
be the case; the negligible vapour pressure means that inducing crystallisation by 
evaporation of the solvent cannot be used. Also ILs are very difficult to purify meaning that 
crystallisation from these solvents may be very difficult as even trace impurities either 
inhibit crystallisation or mean that robust crystallisation processes are difficult to design due 
to the inconsistency in impurities from batch to batch. Another consideration is the vast 
choice of ILs available and to date very little knowledge around the solvation mechanisms 
meaning that the choice of solvent for a given crystallisation may be difficult given the 
number of interactions between ions and solute that can occur. 
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However a number of researchers have recognised that while there are drawbacks to using 
these as media, with the correct strategies in place they could be overcome and the benefits 
of ILs may outweigh some of the perceived disadvantages (Reichert et al, 2006). 
The largest area of crystallisation from ILs that has been conducted to date has been 
crystallisation of inorganic materials. ILs have been used to crystallise a wide range of 
inorganic materials and morphologies. For example Kowacz et al (2011) used ILs to 
precipitate barium sulphate crystals in a range of sizes while Hines et al (2008) used ILs as a 
basis for trapping unique polymorphs of ErCl3(OH2)4•2([C2mim]Cl). Since then a number of 
research groups have investigated the use of ILs in inorganic crystallisations. Ahmed et al 
(2012) reviews current progress in this area, including a wide range of crystallisation 
techniques such as ionothermal, solvothermal, hydrothermal, ultrasonic and microwave 
crystallisations alongside the traditional crystallisation methods. This variety of methods 
produced nano-, micro- and macroscopic crystals show that they are promising media for 
such crystallisations. Crystallisations of organic materials such as APIs will behave very 
differently. However it is promising that ILs have been successfully used as crystallisation 
media in this arena. 
The use of ILs as crystallisation media for proteins has also been reported. Li et al (2008) 
reported the use of [bmim][BF4] to modify the crystallisation of lysozyme from aqueous 
based media where it was found that the presence of [bmim][BF4] both helped to induce 
crystallisation and produced larger crystals than conventional techniques that are more 
suited for single crystal determination. This promising work was followed up by the same 
author (Li et al, 2009) where the work was extended to include thaumatin. In this study they 
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found the ILs [bmim][PF6] to be unsuitable for crystallisation but found that [bmim][BF4] also 
produced large single crystals of thaumatin. The salting out ability of ILs in protein 
crystallisation is described by Kowacz et al (2012) using lysozyme and ribonuclease to 
demonstrate a rank order of ILs based on their hydration properties. ILs that have a large 
polarisable anion with low charge density were found to be the most suited for these types 
of crystallisation. 
Interest in the use of ILs as pharmaceutical solvents was initially down to their proposed use 
as green solvents. This concept was demonstrated by Earle et al (2000) where synthesis of 
the anti-inflammatory and analgesic drug pravadoline was carried out in the ionic liquid 
[bmim][PF6]. The process was designed such that the product (and by-products) could be 
then separated from the IL which could then be re-used in the next reaction. While this 
process is important in highlighting the potential for the reduction in process solvents, it 
should not be assumed that this could be a platform for production of many 
pharmaceuticals, as the molecule used for this demonstration was specifically targeted at 
this sequence of synthesis (regioselective nucleophilic displacement and Friedel-Craft 
reactions). The product and by-products still have to be isolated from the IL through 
distillation or extraction using organic solvent other API chemical processes are unlikely to 
provide the same efficiencies seen here and any new chemical route would need to be 
assessed on a case by case basis. In summary, this is not a platform for all new processes. 
A range of possible crystallisation techniques was discussed by Reichert et al (2006). They 
suggest that while there are a number of challenges to be overcome, ILs may be useful 
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media to carry out crystallisation of organics. However since this publication there has been 
relatively limited progress when compared to inorganic and protein crystallisation. 
In one study two new polymorphs of adefovir dipivoxil (An et al, 2010) were produced from 
an IL-water system. More recently particles <1 µm of rifamoicin were produced using a 
similar crystallisation technique (Viçosa et al, 2012). Using [emim][PF6], amorphous particles 
in the region of 280-360 nm were isolated as a means to improve the bioavailability of this 
compound. The organic compound methyl-(Z)-acetamido cinnamate (MAAC) was crystallised 
from the IL 1-butyl-3-methylimidazolium tetrafluoroborate ([bmim][BF4]) using supercritical 
carbon dioxide as an antisolvent (Kroon et al, 2008). 
Summary of Pharmaceutical Based Research 
The uses of ILs in applications in the pharmaceutical industry have been suggested. 
However, to date much of the research into ILs has focussed on their use either as active 
ingredients or as drug delivery vehicles. Their use in crystallisation studies is limited, with 
most research carried out either in inorganic systems which are not directly relevant to 
organic molecules or as crystallisation aids to producing single protein crystals. The known 
barriers to using ILs as crystallisation media for small molecules, such as their difficulty to 
purify, may be limiting the research in this area. This work aims to investigate the practical 
aspects of performing API crystallisation in ILs to assess whether the suggested benefits and 
drawbacks are encountered. 
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2.5 Crystallisation Theory 
In order to evaluate whether ILs can be used as media to crystallise APIs it is important to 
understand the solution-solute interactions and crystallisation mechanisms involved in the 
formation of crystalline material from a solution.  
2.5.1 Solubility and Supersaturation 
The choice of a suitable solvent for crystallisation can be complicated as the solvent must 
fulfil a number of criteria. One of the main criteria, especially using thermal methods to 
induce supersaturation, is that the API should have a good solubility at high temperatures 
but low solubility at low temperatures to ensure a good product yield.  
If the solute and solvent can be considered to form an ideal solution then the solubility can 
be predicted from the van’t Hoff equation (1903). 
      
   
 
  
 
  
 
 
 
  
                                                                               (2.1) 
where   is the mole fraction of the solute in the solution,   is the solution temperature (K), 
   is the fusion temperature (melting point) of the solute (K),     is the molal enthalpy of 
fusion of the solute (J.mol-1) and R is the gas constant (8.314 J.mol-1K-1). 
The equation can be written in the form       
  
      
   
  
   
   
 
 
                                    (2.2) 
For ideal solutions the a plot of ln   versus T-1 will give a straight line, with the intercept = 
ΔSf/R and the slope = -ΔHf/R. However when the system is non-ideal the slope may differ 
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from –ΔHf/R. In such cases the entropy and entropy of mixing must be taken into account 
such that:                                                                                                                                             
      
   
  
   
   
 
 
(2.3) 
There are various methods available for predicting the solubility that can range from 
relatively simple correlation equations to thermodynamic prediction approaches. If using 
correlation equations then the data set used must be suitable, and it so should not be 
attempted if there is a suspected phase change in the region that is being predicted. For 
example correlation and prediction of solubility data can be completed using a modified 
Apelblat equation (dual parameter equation). 
       
 
 
 
(2.4) 
 
where x is the mole fraction solubility, T is the absolute temperature K and a and b are 
empirical parameters obtained by least-squares fit from the experimental data. Buchowski 
et al (1980) described the behaviour of solid solubility in liquid as the Buchowski equation. 
This equation gave a good description for many solid – liquid systems using two adjustable 
parameters λ and h. 
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While it is possible to describe the equilibrium thermodynamically it is possible to create 
supersaturated systems by, for example, cooling a saturated solution. Creating a 
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supersaturated solution is a requirement for forming crystals from a solution. In order to 
understand how a material forms crystals we must first understand the solution 
thermodynamics of the system by describing when the system is saturated (at equilibrium), 
unsaturated, metastable or supersaturated (labile).  
A representation of the solubility – supersaturation relationship is shown in Figure 2.4. In the   
supersaturated (labile) zone, spontaneous crystallisation followed by crystallisation occurs, 
whereas material in the undersaturated zone will dissolve. The meta-stable zone width is the 
area between super-solubility and the solubility curve. In this region spontaneous 
crystallisation does not occur; however crystals may grow if the solution is seeded or a 
surface on which growth can occur is present. 
 
Figure 2.4: Representation of Stable, Metastable and Labile Regions 
Crystals can only nucleate and grow if the solution is supersaturated; this is the driving force 
for crystallisation in a system. This can be defined as the difference in chemical potential 
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between a molecule in an equilibrium state, µeq and a molecule in its supersaturated state, 
µss. This can be expressed as: 
         
  
    
  
   
    
  
   
     
(2.6) 
where as and xs is the activity and mole fraction respectively of the solute, as and xeq are the 
activity and mole fraction respectively of the solute that is in equilibrium at temperature T, k 
is the Boltzmann constant and S the supersaturation ratio defined as: 
    
 
  
 
(2.7) 
Where c is the solution concentration and c* is the equilibrium concentration for a given 
temperature. 
2.5.2 Nucleation and Growth 
In order to form crystals from a saturated solution the initial formation of a centre of 
crystallisation (seeds, nuclei, dust etc) needs to be present. The nucleation event can be 
described as being primary or secondary. Primary nucleated systems are where there is no 
crystalline material present in the crystallisation and can be further described in terms of 
homogeneous and heterogeneous nucleation. Conversely secondary nucleation describes 
systems where nuclei grow in a system that already contains crystalline material. 
Primary Nucleation - Homogeneous 
Classical nucleation theory relies on the formation of molecular clusters combining to form a 
crystal nuclei. The theory is based on the condensation of a vapour to a liquid, the change in 
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the Gibbs free energy required to form a nucleus of radius r is given by the following 
equations, where γ is the interfacial tension. 
ΔG(r) = -(4πr3/3Ω)kBTln(1+σ) + 4πr
2γ 
(2.8) 
ΔG passes through a maximum denoted as ΔG*. Taking the derivative with respect to r and 
setting this equal to zero allows calculation of rc, the critical cluster size. 
rc = (2Ωγ) / (kBln(1+σ) 
(2.9) 
Inserting this value of rc into the original equation yields the activation energy necessary to 
form a nucleus of the critical size (ΔG*). The process is depicted in Figure 2.5. 
ΔG* = (16πΩ2γ3)/3[kBTln(1+σ)]
2
 
(2.10) 
As the supersaturation of a solution increases, both the barrier for the critical activation 
energy and the value of the critical size decrease. As the degree of supersaturation 
increases, the activation energy becomes so low that spontaneous and rapid nucleation 
occurs. These crystallisations require the system to be in high supersaturation and even then 
without a surface to grow on many materials will not nucleate. 
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Figure 2.5: Gibbs Free Energy Change for Homogeneous Nucleation 
Primary Nucleation - Heterogeneous 
Heterogeneous nucleation is more common in industrial crystallisation than homogeneous 
nucleation. In this case, a foreign particle acts as a centre for nucleation by lowering the 
energy barrier required to form nuclei. The value of γ is lowered which lowers the value of 
ΔG*. 
Secondary Nucleation 
This is used to describe systems where seed material is present. The seed acts as a centre for 
growth and means that the nucleation can occur at much lower supersaturations. This is a 
common techniques used in pharmaceutical production as a means to control either the 
crystal form and/or crystal habit.  
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While Classical Nucleation Theory (CNT) has proved to be a sufficient for describing the 
kinetics of the process, new theories on nucleation have focussed on the evolution of 
structure ,in particular, the competing nature of crystallisation in a polymorphic system. CNT 
suggests that the formed clusters reflects all possible polymorphs of the solute and the 
crystal nuclei have the same structure as a mature crystal. New proposed mechanisms of 
nucleation have been described, Vekilov (2010) describes a two step process in which 
crystalline order is preceded by the separation of a dense disordered liquid phase, as often 
observed in protein crystallisation (Tosi, 2011). Also Gebauer and Cofen (2011) reviewed 
evidence for ‘pre-nucleation clusters’ seen predominately in inorganic systems. This has led 
to non-classical theory in which the crystalline order is preceded by the separation of a 
dense, disordered liquid phase and fluctuations in density are disconnected from 
fluctuations in order. Initial clusters are liquid like and crystalline order appears overtime. 
2.5.3 Crystal Growth 
Once stable nuclei have been established they can grow into crystals. A number of theories 
and refinements have been proposed to explain the theory of crystal growth and they can be 
broadly categorised into three types: surface energy, adsorption and diffusion theories. 
Surface energy theory suggested by Gibbs (1948) is based on crystals assuming a shape 
which gives a surface area minimum. Data to support this theory are lacking and it also fails 
to explain some known important effects such as supersaturation and solution movement 
on crystal growth. These drawbacks mean that currently surface energy theories are not 
generally used to explain crystal growth. 
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Adsorption layer theory was first introduced by Volmer in 1939. When solute molecules 
(growth units) arrive at the surface of a crystal they are loosely absorbed, free to migrate 
over the crystal surface, creating a dynamic equilibrium between this layer and the bulk 
solution. The absorbed growth units will attach into the lattice where the attractive forces 
are the strongest, where, under ideal conditions, a whole new plane face is completed. Once 
this plane has been fully formed in order for a new plane to begin, a new crystallisation 
centre must form. It was suggested that growth units form a monolayer island nucleus, other 
growth units then adding to this island to complete the next plane. 
The mechanism as to how these growth units add into crystals has been refined by a number 
of researchers. They acknowledge that the crystals do not grow in the ideal layer by layer 
without imperfections occurring as described in Volmers model. The dislocations cause steps 
or kinks, acting as locations for growth units to add into. The mechanisms of how crystal 
growth occurs can be described in terms of continuous growth, surface nucleation and spiral 
growth. 
Continuous growth assumes that the energy to form a step is low. Therefore the surface will 
be rough, containing many kink and step sites so material arriving at the surface easily finds 
a site to attach. 
As the roughness of the interface decreases not all of the growth units will find a growth site. 
They will either return to the fluid phase or join other adsorbed growth units to form 
‘surface islands’. These islands then act as step or kink sites where additional material can 
join and continue growth of the crystal. 
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If the surface is flat, growth can only occur if a step can be created. This occurs from lattice 
defects called dislocations where part of the crystal becomes misaligned with the rest of the 
crystal. Screw dislocations only extend over only part of the surface and during growth wind 
up into a spiral. The kinetic theory for this was developed by Burton, Cabrera and Franck 
(1951) and is more commonly referred to as the BCF theory. 
Diffusion theory can be traced back to the work of Noyes and Whitney (1897) and is based 
on the understanding that crystal growth is driven by the difference in concentration of solid 
crystal surface and the bulk solution. The diffusion theory was refined by Berthoud (1912) 
and Valeton (1924) who suggest that there were two steps involved whereby the diffusion of 
solute molecules to the solid surface is followed by a first order reaction to arrange the 
molecules into the lattice.   The diffusion step is widely believed to be linearly related to the 
concentration difference however the assumption of a first order reaction is not supported. 
Although it is recognised that diffusion theories have deficiencies, crystal growth rates are 
still measured and reported in diffusion terms.  
The morphology (crystal habit) depends on the relative growth rates of the crystal faces. It is 
therefore the slowest growing faces that have the biggest influence on the morphology of a 
crystal. 
2.5.4 Polymorphism 
Understanding and delivering the correct form of an API is fundamental to the 
pharmaceutical industry for three main reasons: firstly different forms of API have different 
solubilities and hence can impact the bioavailability of a drug product; secondly it is 
important that the form of API produced is stable and does not interconvert to another form 
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during downstream processing, packaging and storage; and thirdly different forms of an API 
can be patented separately so that understanding the various forms for a given API is 
important for securing the intellectual property. 
The form or polymorph of a substance is used to describe the unique packing order of the 
unit cell. Although chemically the same some substances can pack together in a different 
arrangement giving rise to polymorphism or different forms.  Crystalline material is 
organised into a series of repeating units, these unit cells will form one of seven possible 
crystal systems; regular, tetragonal, orthorhombic, monoclinic, triclinic, trigonal and 
hexagonal are shown in Table 2.4. 
System Other Names Angles 
between axis 
Length of 
axis 
Examples 
Regular Cubic 
Octahedral 
Isometric 
Tesseral 
ά = β = γ = 90°       Sodium Chloride 
Potassium Chloride 
Alums 
Diamond 
Tetragonal Pyramidal 
Quadratic 
ά = β = γ = 90°       Rutile 
Zircon 
Nickel Sulphate 
Orthorhombic Rhombic 
Prismatic 
Isoclinic 
Trimetric 
ά = β = γ = 90°       Potassium Permanganate 
Silver Nitrate 
Iodine 
ά- Sulphur 
Monoclinic Monosymmetric 
Clinorhombic 
Oblique 
ά = β = 90° ≠ γ        Potassium Chlorate 
Sucrose 
Oxalic Acid 
β - Sulphur 
Triclinic Anorthic 
Asymmetric 
ά ≠ β ≠ γ ≠ 90°       Potassium Dichromate 
Copper Sulphate 
Trigonal Rhombohedral ά = β = γ ≠ 90°       Sodium Nitrate 
Ruby 
Sapphire 
Hexagonal None z axis is 
perpendicular 
to the  , y and u 
axes, which are 
inclined at 60° 
         Silver Iodide 
Graphite 
Water (ice) 
Potassium Nitrate 
Table 2.4: The Seven Crystal Systems (re-created from Mullin) 
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More than 80% of crystalline elements and inorganic compounds are either regular or 
hexagonal. As molecules become more complex then orthorhombic and monoclinic systems 
are favoured.  
When a solid crystallises from solution it can either be under thermodynamic or kinetic 
control. If it is thermodynamically controlled then the solvent used is immaterial. However if 
under kinetic control then in some cases the choice of solvent can influence the resultant 
crystal structure and hence crystallise meta-stable forms. If a form is meta-stable then it will 
covert in time to the thermodynamically stable polymorph; this process can take a matter of 
minutes to years.  
This phenomenon can be described in Ostwald’s rule of stages (Liesegang, 1911) where he 
stated that an unstable system will not directly convert to the most stable state but to a 
state that results in the smallest loss of free energy. Exceptions to this rule are known to 
exist but it provides an important consideration when crystallising molecules that are either 
known to or predicted to have multiple polymorphic forms. 
2.5.5 Crystallisation Methods 
There are various methods that can be employed to generate the supersaturation required 
to crystallise APIs. By far the two most common methods used to do this are cooling 
crystallisation or anti-solvent crystallisation.   
In cooling crystallisation methods the temperature of the solution is lowered so that is below 
the saturation concentration of the solution. Spontaneous crystallisation will occur when the 
solution is cooled sufficiently that it becomes supersaturated to such an extent that it 
crosses the metastable zone and forms crystals as there is enough energy in the system to 
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form stable nucei. Alternatively once in the meta-stable zone width (MSZW) crystallisation 
can be initiated using seed crystals which grow as the solution becomes de-supersaturated.  
Factors to consider when designing a cooling crystallisation include: the solubility gradient 
such that at higher temperatures sufficient material can be dissolved in solution in order to 
design a process capable of being scaled into an appropriate reactor while having a low 
enough solubility at the isolation temperature to ensure commercially viable yield is 
obtained from the process. The rate of cooling also needs to be considered as it is more 
likely that kinetically favoured forms can be isolated when higher cooling rates are used 
whereas, in general, it is the thermodynamically favourable form that is usually desired. If 
trying to control the particle size through crystal growth then slow cool is preferred over fast 
to avoid any secondary nucleation events. 
Evaporative crystallisation is also used to generate saturated solutions for crystallisation. 
This is achieved by heating a solution to its boiling point. As solvent evaporates the 
concentration of the solution increases. The surface from which the evaporation occurs 
becomes more supersaturated than the bulk solution, forming crystals at the surface. 
Crystals can then fall back into the bulk solution and grow. Although it has been shown that 
some ILs can be distilled (Earle et al, 2006) it is not practically possible to use the majority of 
ILs for such processes and this was not considered as a viable method for this work. 
Antisolvent crystallisation is a commonly used method to induce crystallisation where the 
solution containing the compound is mixed with a solvent where the solute has low or 
negligible solubility. The mixed solvent system has a lower solubility and hence the 
possibility for generating supersaturated solutions. The technique can be especially useful 
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for materials where temperature has little impact on the solubility and materials that are 
unstable at high temperatures. To ensure that regions of higher saturation within the 
solution are minimised then the antisolvent should be added slowly under good mixing. 
Adding the antisolvent too quickly increases the risk of forming and isolating kinetically 
favourable forms but also increases the chance that impurities can be included into the 
crystal, which if uncontrolled can result in batches failing specification. 
Reactive crystallisation works by adding one reactant to a solution of another causing a 
chemical reaction. The resulting product has a lower solubility and crystallises out of 
solution. Reactive crystallisations have been carried out in ILs but have not been considered 
as this work is more focussed on the physical control of API rather than formation through 
chemical synthesis. However this remains a possible method that could be used with ILs. 
An alternative crystallisation method that may be suitable in combination with ionic liquids 
is the use of SuperCritical Fluids (SCF). The most applicable strategy to any potential IL 
crystallisation is commonly referred to as the Gas Anti-Solvent (GAS) process, where the 
supercritical fluid is used as the anti-solvent. A SCF is a substance, commonly CO2, that is 
above its critical temperature and pressure. When in this physical state  they possess unique 
properties that can give them the diffusivity of a gas but the solvation power of a liquid. 
When brought into contact with a solution containing API saturation point is rapidly reached 
promoting nucleation very quickly, which depending on the equipment set-up can produce 
small particles. 
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2.6 Summary 
This review highlights that, compared to conventional solvents, ILs have unique properties 
which have been exploited by some industries to develop new chemical processes. While 
some potential applications for their use in the pharmaceutical industry have been reported 
little has been done to assess their suitability as a medium for crystallisation of API. This 
work looks to address this gap by establishing if the unique properties of ILs could provide 
any benefits to crystallising APIs and in particular if they could be used to modify physical 
properties.  
The following chapters detail the work undertaken to establish this and includes details on 
the materials and methods used followed by studies conducted with paracetamol, ibuprofen 
and flufenamic acid and finishes by providing details of the practical issues encountered 
during this work. The conclusions from the work with thoughts as to further work in the field 
are provided at the end of this thesis. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Introduction 
This chapter introduces the materials and methods that were used throughout this work. It 
provides a rationale as to the selection of the materials used and baseline data on the 
specific materials used in this study such that any of the reported work could be repeated. 
3.2 Materials 
The nature and sourcing of materials used in this work are described in the following 
sections. A summary of all the materials used is provided in Tables 3.2 and 3.3. 
3.2.1 Rationale for IL Selection 
The primary aim of the thesis was to investigate the possibility of using ionic liquids as 
crystallisation media. It was decided therefore to source these materials from suppliers 
rather than to synthesise in the laboratory. 
Given the large number of possible ionic liquids that could be used in this study a rationale 
for the selection was required. The criteria used were: 
1. Needed to be commercially available 
2. To be a liquid at or around room temperature 
3. Have a purity >95% 
4. Cost <£2 per g 
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There are a number of suppliers of ionic liquids that operate at a range of scales from gram 
to multi-ton and offer various ranges of products that, due to the nature of IL research, are 
ever changing and evolving. The suppliers assessed during this work were: 
1. Merck Chemicals 
2. BASF 
3. Cytec 
4. Scionix 
5. IoLiTec 
6. Sigma Aldrich 
A traffic light system was used to assess the products from these suppliers against the 
required criteria; details are shown in Table 3.1.  
From this assessment in order to complete as systematic a study as possible given the ILs 
currently commercially available, it was decided to base the studies on the 1,3-
methylimidazolium cation. This cation is by the most researched cation in IL studies and 
fulfilled many of the criteria needed for this work. Anions were then selected to provide a 
range to assess the impact of the crystallisation of the model compounds. The ionic liquids 
used in this study are displayed in Table 3.2. 
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Table 3.1: IL Selection Criteria 
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Material Structure Purity Source Batch 
[bmim][PF6] 
 
99% Merck 
S9587950 
917 
[hmim][PF6] 
 
98% Merck 
S5205765 
922 
[bmim][BF4]
  
 
>98% BASF BCBK6686V 
[bmim]              
[C8H17OSO3] 
 
>95% Sigma BCBJ9526V 
[bmim][NTf2] 
 
>98% BASF BCBJ5958V 
[bmim]  
[CH3COO] 
 
>95% BASF STBC9122V 
Table 3.2: Ionic liquids Used in Practical Work 
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3.2.2 Rationale for Model API Compounds 
Three model compounds were selected for this investigation. They were acetaminophen 
(commonly known as paracetamol),  ibuprofen and flufenamic acid. 
Paracetamol is a well known active pharmaceutical ingredient used to treat pain that has 
been used in market products since 1953. It can be considered to be a polar molecule that is 
freely soluble in water.  Ibuprofen is also a well established active pharmaceutical that has 
been marketed since 1969 for pain relief and to reduce swelling. Ibuprofen is less polar than 
paracetamol and as such is poorly soluble in water. Flufenamic acid is a potent anti-
inflammatory API used in the treatment of osteoarthritis, rheumatoid arthritis and other 
painful musculosketal illnesses. Flufenamic acid is known to be highly polymorphic with eight 
polymorphs having been reported in the literature. These three molecules represent 
different scenarios when choosing a solvent for crystallisation and so were chosen as good 
model compounds for this study. A summary of the materials used their source and the 
grade or purity used is shown in Table 3.3. 
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Material Structure Grade or 
Purity 
Source Batch 
Paracetamol 
 
>99% Merck S3876440 
424 
 
Ibuprofen 
 
>98% Sigma SLBF2671V 
Flufenamic Acid 
 
>97% Alfa 
Aesar 
B23583 
Table 3.3: Purity and Source of Materials Used 
3.2.3 Model Compound Characterisation 
Paracetamol 
The paracetamol was used as supplied from Merck. Baseline analysis was completed on this 
material to determine: form, melting point, particle size and habit, were assessed by XRD, 
DSC, laser diffraction and microscopy. The diffraction pattern of the input material was 
concordant with the reference for monoclinic form I material (Haisa, 1975) as shown in 
Figure 3.1 
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Figure 3.1: Overlay of Input Paracetamol (red) and Monoclinic Form I Reference (blue) 
(Haisa, 1975) 
Thermal analysis by DSC, shown in Figure 3.2, shows an onset of melt at 169.01 °C with the 
melting point recorded at 169.78 °C which is consistent with literature data for this form. No 
other thermal events were bserved.  
 
 
 
 
 
 
 
 
Figure 3.2: DSC Trace of Input Paracetamol 
Particle habit was analysed by optical and scanning electron microscopy shown in Table 3.4. 
The images show the primary particles to have an irregular shape with a broad range of 
particle sizes observed in the sample. 
Position [°2Theta] (Copper (Cu))
10 15 20 25 30
Counts
0
50000
100000
0
5000
 Simple Sum_1_XRPD_Paracetamol_Input
 Monoclinic Paracetamol
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Table 3.4: Optical and Scanning Electron Microscopy of Input Paracetamol 
The particle size distribution shown in Figure 3.3 confirms the wide particle size range 
observed with the d10, d50 and d90 values measured as 11 µm, 47 µm and 199 µm 
respectively. The distribution is multi-modal showing multiple populations of particles 
observed giving calculated span of 4.0. 
 
Figure 3.3: Particle Size Distribution of Input Paracetamol 
Ibuprofen 
Ibuprofen was used as supplied from Sigma Aldrich. The same analyses were completed to 
obtain baseline data for the input. 
The diffraction pattern of the input was concordant with Form I material and is displayed in 
Figure 3.4. 
Optical Microscopy Scanning Electron Microscopy 
50X Magnification 100X Magnification 250X Magnification 500X Magnification 
    
54 
 
 
Figure 3.4: XRD Pattern of Input Ibuprofen (red) and Form I Reference (blue) 
Thermal analysis by DSC shows an onset of melt at 74.04 °C with the melting point recorded 
at 76.74 °C which is consistent with literature data for this form. No other thermal events 
were observed. The obtained trace is shown in Figure 3.5. 
 
Figure 3.5: DSC Trace of Input Ibuprofen 
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Particle habit was as analysed by optical and scanning electron microscopy shown in Table 
3.5. The images show the primary particles to plate shaped with broad range of particle sizes 
observed in the sample. 
Table 3.5: Optical and Scanning Electron Microscopy of Input Ibuprofen 
The particle size distribution shown in Figure 3.6 shows a reasonable control of the particle 
size with the d10, d50 and d90 values measured as 21 µm, 57 µm and 126 µm respectively. The 
span for the input ibuprofen was calculated as 1.8. 
 
 
 
 
 
Figure 3.6: Particle Size Distribution of Input Ibuprofen 
 
 
 
Optical Microscopy Scanning Electron Microscopy 
50X Magnification 100X Magnification 250X Magnification 500X Magnification 
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Flufenamic Acid 
The input flufenamic acid was analysed by XRD, DSC and optical and scanning electron 
microscopy. The size of the input was not determined as particle size was not deemed 
relevant to the crystallisation studies.  
For reference the XRD on the input batch was completed and the obtained diffraction 
pattern is shown in Figure 3.7. 
 
Figure 3.7: XRD Analysis of Input Flufenamic Acid 
DSC analysis, Figure 3.8,  shows the onset of melt of the material at 133.57 °C with the 
melting point recorded at 136.41 °C which is the melting temperature of form I. No 
exothermic transition was detected prior to the melt. 
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Figure 3.8: DSC Analysis of Input Flufenamic Acid 
The images obtained from optical microscopy and SEM show large tabular crystals which are 
>300 µm are displayed in Table 3.6. 
Table 3.6: OM and SEM Images of Input Flufenamic Acid 
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3.3 Methods 
Methods used to prepare and analyse materials used in this thesis are described in the 
following sections. This includes details on the development of a method to measure the  
equilibrium solubility of API in ILs. Followed by details of how the MSZW was established for 
the systems of interest. The equipment and methodology used to conduct various small 
scale crystallisations and how the resultant precipitated products were analysed are then 
provided. 
3.3.1 Solubility 
Paracetamol and Ibuprofen in [bmim][PF6], [hmim][PF6] and water 
An excess of a compound was added to approximately 5 ml ionic liquid or water in a sealed 
glass vial. The vial was loaded into the heater block of a ReactArray unit (AnaChem, UK). The 
sample was held at the desired temperature for >24 hours under agitation (magnetic flea at 
900 rpm) to ensure that the saturation solubility was reached. The temperature of the block 
was measured using an independent, calibrated type K thermocouple (±0.1 K) to ensure that 
the sample was held at the desired temperature. The solution was stirred until saturation of 
the drug in solution was achieved which was shown by analysing the amount of solute 
dissolved by UV over time. Saturation was found to be reached after 22 hours, and 
consequently all samples were left for at least 24 hours.  
At each temperature point an aliquot of the saturated solution was removed using an oven-
heated (5 K above sample temperature) plastic syringe (2.5 ml syringe) fitted with a PTFE 
filter 0.5 ml (Whatman filter, 0.4 μm filter). The heated syringe was necessary to avoid 
precipitation of the solute due to temperature fluctuation during sampling. The sample was 
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then diluted with 2.5 ml methanol and the drug content determined by UV 
spectrophotometry using a diode array spectrophotometer (HP 8452A) against a standard 
curve for the compound in solution (for all curves R2>0.996). Where necessary, further 
dilution was carried out to ensure that the measured absorbance was within the standard 
curve. The volume of ionic liquid and methanol or water was determined from the 
graduated scale of the syringe (±0.1mL) and was used as the volume in the solubility 
determination. For paracetamol solubility studies, data were obtained at λmax = 250 nm in 
[bmim][PF6] and [hmim][PF6], and λmax = 245 nm in water. For ibuprofen, data were 
obtained at λmax = 264 nm for [bmim][PF6] and [hmim][PF6] and λmax = 222 nm for water. 
Three independent samples were analysed for each temperature point and each sample was 
measured three times. The temperature–solubility profiles were then determined for 
ibuprofen and paracetamol in [bmim][PF6], [hmim][PF6] and water. 
Solubility for Paracetamol and Flufenamic Acid Scoping work 
A slurry sample was prepared in an HPLC vial fitted with a screw top; the slurry was heated 
to the desired temperature using a mini-reactor. The sample was held at the desired 
temperature for >24 hours under agitation (magnetic flea at 900 rpm) to ensure that the 
saturation solubility was reached. The temperature of the block was measured using an 
independent, calibrated type K thermocouple (±0.1 K) to ensure that the sample was held at 
the desired temperature. An aliquot of the sample was weighed into a HPLC vial by filtering 
through a PTFE filter (Whatman filter, 0.2 μm filter). The vial was diluted with methanol and 
re-weighed to calculate the dilution factor. Samples were run on an HPLC Linear gradient 
from 0 to 95% acetonitrile over 3 minutes at 60 °C and 1.5 mL/min on a Zorbax SB-C18 3x50 
mm, 1.8 μm column (part number 884950-576). The concentration was determined from 
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pre-determined calibration curves in the same solvent. Each sample was run in duplicate 
with the average result reported. 
3.3.2 Meta-Stable Zone Width  
The meta-stable zone width (MSZW) was determined by a polythermal technique using an 
Avantium Crystal 16™ which consists of four independently heated aluminium blocks with 
turbidity measurement on each vial using light transmission. It has an accuracy of (±0.1 K). A 
known excess of model compound was added to 0.5 mL(±0.01 mL) IL to give a range of 
concentrations. The solutions were then heated under agitation (700 rpm) at a heating rate 
of 0.2, 0.5 or 1.0 K.min-1 to 263 K in order to achieve full dissolution of the solid. The 
solutions were cooled at the same rate to 288 K. The point at which crystals could be 
detected (the cloud point) was used in combination with the equilibrium solubility to 
determine the MSZW for the measured IL and the model compound system. 
3.3.3 Cooling Crystallisations 
All crystallisations were carried out in a 60 mL glass vessel with overhead stirring (500rpm); 
temperature and stirring were controlled using a Mettler Toledo Multimax™. For the non-
seeded experiments, a desired mass of paracetamol was added to 20 mL (±0.5 mL) IL and 
heated to >353 K in order to achieve full dissolution, then cooled at 0.2 K.min-1 to 293 K. 
Crash cooling experiments were also performed on the same equipment at a cooling rate of 
10 K.min-1. For the seeded experiments, the solutions were cooled to 333 K, seeded with 20 
mg of input seed, and held for 4 hours before cooling to 293 K at 0.2 K.min-1. In all cases the 
precipitate was recovered by vacuum filtration (750 mbar).  
61 
 
3.3.4 Anti-Solvent Crystallisation 
An anti-solvent crystallisation was performed on the same equipment to determine the 
impact of an additional solvent on the filtration time. In this case dichloromethane was 
added to a final ratio of 80:20 vol:vol using the multimax syringe pumps. A small condenser 
was attached to the vessel to reduce the loss of solvent as vapour.  
3.3.5 SCF Crystallisation 
Experiments were performed using a stainless steel pressure vessel equipped with a viewing 
port and a heating jacket with circulating silicon oil, Figure 3.9. The sample contained in a 
HPLC vial was lowered into the pressure vessel. After the sample vial was lowered, the vessel 
was sealed and the CO2 was added to the required pressure. CO2 entered the pressure vessel 
from a liquid withdrawal cylinder at 55 bar via stainless steel tubing. CO2 was further 
pressurised using a manual pump. The manual pump worked like a piston and was covered 
with a coil containing circulating refrigerant to cool the CO2 and ease pressurisation. The 
flow rate of CO2 into the pressure vessel was controlled using valves V1, V2 and V3. At the 
end of the experiment CO2 was vented to the atmosphere using valves V4 and V5. 
 
 
 
 
 
 
 
Figure 3.9: Equipment set-up for scCO2 Crystallisation 
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3.3.6 Analysis 
Analysis of the crystallised products and the starting materials was carried out using the 
procedures below. 
X-Ray Diffraction 
Samples were prepared by adding approximately 25 mg of material into a single well in a 96 
well plate. The samples were scanned three times and an average of the three scans taken. 
The diffraction patterns were obtained using a PANalytical Empyrean diffractometer in 
transmission mode using the following parameters: 
 
 
Imaging Techniques 
Particles were analysed by optical microscopy using a Olympus BX51 fitted with a CoolSNAP-
Pro camera), using Image-Pro Plus software (Version 4.5). Samples were prepared by 
dispersing a small amount of material in oil with a glass slide placed on top of the sample. 
Scanning electron microscopy was carried out using a Hitachi TM-1000. Using a adhesive 
carbon disc mounted on an aluminium stub. A small amount of sample was dispersed onto 
the carbon disc and the sample was then analysed using an accelerated voltage of 15000 
Volts (note the sample was not coated). 
Scan Axis: 2Theta only 
Start Position [°2Th.] 1.9975 
End Position [°2Th.] 34.9915 
Step Size [°2Th.] 0.0260 
Scan Step Time [s] 175.1850 
Scan Type Continuous 
Divergence Slit Type Fixed 
Divergence Slit [°] 0.4354 
Receiving Slit Size [mm] 0.1000 
Temperature [°C] 21.00 
Anode Material Cu 
K-Alpha1 [Å] 1.54060 
K-Alpha2 [Å] 1.54443 
K-Beta [Å] 1.39225 
K-A2 / K-A1 Ratio 0.50000 
Generator Settings 40 mA, 45 kV 
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Particle Size  
Particle size was measured by laser diffraction using a Malvern Mastersizer 2000. The 
dispersants used for the model compounds were different: iso-octane with 0.05%w/w 
lecithin was used for paracetamol and water used for ibuprofen. To prepare the sample a 
small amount (approximately 100mg) of material was placed in 2mL of dispersant. The 
sample was sonicated for 30 seconds at 25% power. The Malvern was flushed with the 
diluents and, when clean, a background measurement was taken. The sample was then 
added to give a obscuration of between 2 and 10% before analysing the sample three times. 
An average of the three results was reported, along with the span of the distribution (d90-
d10/d50). It should be noted that the calculation of particle size was based on Fraunhofer 
theory and assumed particle sphericity which was not seen, nor expected, for the crystals 
obtained from any of the solvent systems. 
Differential Scanning Calorimetry 
When samples were analysed by differential scanning calorimetry the following procedure 
was used. Small amount of sample (1-5mg) was accurately weighed into an aluminium pan. 
An aluminium lid was placed on top of the pan and lightly crimped. The sample was analysed 
using a TA Q200. The pan was allowed to equilibrate at 298 K before a standard ramp of 10 
K.min-1 was started. 
3.4 Conclusions 
This chapter discussed how the selected materials were prepared and characterised.  Detail 
on the experimental protocols and methods are give such that any of the work in the 
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following chapters could be repeated. The chapter has also reported the physical properties 
of the input API materials used for the study. 
3.5 References 
Haisa, M., Kasjino, S., Kawai, R., Maeda, H., (1975) The Monoclinic Form of p-
Hydroxyacetanilide, Acta Cryst., B32, 1283 
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CHAPTER 4: STUDIES WITH PARACETAMOL 
4.1 Introduction 
This chapter is focussed on the experimental work completed on paracetamol. Starting first 
by outlining the methodology used to determine the solubility of paracetamol in the ILs 
[bmim][PF6] and [hmim][PF6] the results were then assessed using solubility correlations to 
understand if these models could be applicable to such systems. 
Using these unique solvents a series of cooling crystallisations were designed and 
completed. The Meta-Stable Zone Width (MSZW) was established and combined with the 
solubility data to design a series of cooling crystallisations. The crystallisations assessed the 
impact that nucleation mechanism and concentration had on the crystal form, habit and size 
of the resultant crystals.  
A protocol for screening further ILs was then developed and used to assess a homologous 
series of ILs to determine the impact of changing the anion on the physical form of 
crystallised material. 
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4.2 Solubility  
4.2.1 Validation of Solubility Method – Solubility in Water 
Before the solubility was determined in any ILs the methodology was established by 
analysing the solubility in water and comparing to literature values. Solubility data were 
determined between 298.15 K and 338.15 K in 10 K increments. For each measurement the 
overall mean from three experiments plus or minus the standard error of the mean were 
calculated for both the absorbance and solubility. 
A summary of the data are shown below in Table 4.1. The raw data obtained from the UV 
spectrophotometer with corresponding solubility data in mg solute per mL water can be 
found in Appendix 1. 
Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
298.15 1.130 ± 0.018 19.16 ± 0.31 
308.15 1.497 ± 0.052 25.45 ± 0.88 
318.15 2.023 ± 0.072 34.45 ± 1.23 
328.15a 1.533 ± 0.063 51.60 ± 2.14 
338.15a 1.974 ± 0.055 66.55 ± 1.85 
a 
The absorbance values are out of line for 328.15 K and 338.15 K due to additional dilution of the samples. 
 Table 4.1: Solubility of Paracetamol in Water 
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
The solubility of paracetamol ranged from 19.16 mg.mL-1 to 66.55 mg.mL-1 across the 
temperature range studied which, according to the US Pharmacopeia definition (U.S. 
Pharmacopeia, Section 5.30), means that paracetamol can be described as being sparingly 
soluble to soluble. The standard errors of the mean obtained at these temperatures were all 
<2.14 mg.mL-1 showing that all the samples were in reasonable agreement.  
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Data obtained in this work were plotted against literature data (Etman, 1990), (Granberg, 
1999) and (Garekani, 2003), Figure 4.1, to determine if the method used provided 
comparable results.  
 
This work ■, Granberg et al ∆, Etman et al x and Garekani et al + 
Figure 4.1: Solubility Data in Water as a Function of Temperature for Paracetamol 
The solubility data for paracetamol data measured in this work are in good agreement with 
other laboratories and also extends to higher temperatures than has been reported in the 
literature.  This gives confidence that the methodology used in this work is suitable for the 
purposes of establishing equilibrium solubility data for crystallisation development. 
4.2.2 Solubility  in Ionic Liquids 
Using the same methodology the solubility of paracetamol was determined in the ILs 
[bmim][PF6] and [hmim][PF6] across the temperature range 298.15 K to 338.15 K at 10 K 
increments. A summary of the data is shown below in Tables 4.2 and 4.3 for [bmim][PF6] and 
[hmim][PF6] respectively. The raw data obtained from the UV spectrophotometer with 
corresponding solubility data in mg solute per mL can be found in Appendix 1.  
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Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
 298.15 0.579 ± 0.011 6.95 ± 0.14 
308.15 0.829 ± 0.059 10.05 ± 0.73 
318.15 0.907 ± 0.102 11.01 ± 1.26 
328.15a 1.282 ± 0.009 15.67 ± 0.11 
338.15a 1.880 ± 0.018 23.09 ± 0.23 
Table 4.2: Solubility of Paracetamol in [bmim][PF6] from T = 298.15 K to 338.15 K 
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
298.15 0.991 ± 0.085 13.21 ± 1.17 
308.15 1.138 ± 0.032 15.22 ± 0.44 
318.15 1.547 ± 0.100 20.86 ± 1.38 
328.15a 1.931 ± 0.048 26.13 ± 0.67 
338.15a 2.242 ± 0.223 30.40 ± 3.06 
Table 4.3: Solubility of Paracetamol in [hmim][PF6] from T = 298.15 K to 338.15 K. 
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
Solubility values of 6.95 mg.mL-1 to 23.09 mg.mL-1 were obtained for [bmim][PF6] and 26.38  
mg.mL-1 to 120.41mg.mL-1 for [hmim][PF6] across the same temperature range. This would 
rank paracetamol as ranging from slightly soluble to sparingly soluble in [bmim][PF6] and 
sparingly soluble to freely soluble in [hmim][PF6] across the temperature range studied. The 
samples were all in good agreement with standard error of the mean of <1.26 mg.mL-1 and 
<3.06 mg.mL-1 obtained for [bmim][PF6] and [hmim][PF6] respectively. The data were plotted 
together with the solubility data in Figure 4.2. 
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water ♦, [bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 4.2: Paracetamol Equilibrium Solubility Data 
Solubility as a function of temperature for Paracetamol. Each point represents the overall 
mean  from three independent experiments ± the standard error of the mean. 
 
For all solvents tested the solubility was found to increase with temperature. Although 
paracetamol was found to have a reasonable solubility in both ILs, indicating drug-solute 
interactions, the solubility was less that in water. The O-H and N-H bond can form hydrogen 
bonds, giving paracetamol good solubility in polar and medium polar solvents (Granberg, 
1999), whereas the hydrophobic PF6 anion in these ILs makes solvation less favourable, 
reducing the solubility compared to water as expected. However the solubility in 
[hmim][PF6] was found to be higher than [bmim][PF6]. This was an unexpected result as the 
longer alkyl chain length makes [hmim][PF6] more hydrophobic. The rationale as to the 
reason for this is not straightforward as the solvation mechanisms and drug-solute 
integrations of ILs are still relatively unknown. The increase in the alkyl chain length 
increased the hydrophobicity and viscosity but reduces the density and surface tension. 
However the purity of the IL should also not be overlooked. The [bmim][PF6] used was 
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supplied with a purity 99% while the [hmim][PF6] supplied was 98% pure. While this may be 
considered to be a relatively small difference in purity this may have a significant impact on 
the solubility of paracetamol.  
4.2.3 Modelling Paracetamol Solubility Data 
van’t Hoff 
 
If the solvent and solute are assumed to form an ideal solution then dissolution enthalpy 
(ΔHd) and entropy (ΔSd) can be predicted from the van’t Hoff equation (equation 2.1). The 
van’t Hoff plots are shown in Figure 4.3 
 
Water ♦, [bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 4.3: van’t Hoff plot of Paracetamol 
The dissolution entropy can be approximated by extrapolating the data while the entropy 
can be approximated from the slope of the trend line. The obtained values are shown in 
Table 4.4 
 
-7 
-6 
-5 
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0.0029 0.003 0.0031 0.0032 0.0033 0.0034 
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x 
1/T 
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Table 4.4: Dissolution Enthalpy and Entropy Values from van’t Hoff Plot 
In each case values of ΔHd  > 0 and thus the solvation process is endothermic indicating that 
the interactions between paracetamol and the solvents are not strong enough to break 
down the energy of attraction of the paracetamol molecules with each other and the 
electrostatic interactions of the IL cation and anion. Positive values of ΔSd were also 
obtained indicating that the paracetamol-solvent system became increasingly disordered as 
temperature was increased. 
Dual Parameter 
A simplified dual parameter equation, (        
 
 
  ,was used to determine if the 
solubility results could be fitted using this. The values of A and B were obtained by least 
squares fit from the experimental data.  
The calculated parameters for the dual parameter equation are displayed in Table 4.5 
together with the root mean square deviation. Using the parameters the solubility was 
calculated using the dual parameter equation and are compared together in Table 4.6. The 
experimental data and calculated data were plotted together in Figure 4.4. 
Dual Parameter Equation 
IL A B 103rmsd 
[bmim][PF6] 4.989 -2788.8 2.006 
[hmim][PF6] 3.505 -2135.8 1.352 
Table 4.5: Calculated A and B Parameters and Root Mean Square Deviation 
Solvent Water [bmim][PF6] [hmim][PF6] 
ΔHd  
kJ.mol-1 
26.65 41.47 17.76 
ΔSd  
 J.mol-1.K-1 
38.48 23.18 29.14 
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T / K 103 exp 103 1
cal 
[bmim][PF6] 
298.15 12.893 12.718 
308.15 18.543 17.229 
318.15 20.285 22.898 
328.15 28.611 29.910 
338.15 41.596 38.456 
[hmim][PF6] 
298.15 26.559 25.775 
308.15 30.485 32.520 
318.15 41.297 40.436 
328.15 51.199 49.615 
338.15 59.083 60.145 
Table 4.6: Comparison of Experimental Data and Calculated Values of Solubility 
 
[bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 4.4: Experimental data points (solid points) and fitted data (dotted line) 
The calculated results from the dual parameter equation are in good agreement with the 
experimental values. While it is recognised that the solvation mechanisms of ILs are not fully 
understood the data shows that simplified correlations such as the ones used here could 
potentially be used as a tool to provide  solubility trends of APIs in ILs. 
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Buchowski  Equation 
The relationship between mole fraction solubility and temperature on the solid-liquid phase 
equilibrium was also assessed using the λh (Buchowski) equation, (      
   
 
  
     
 
  
  
 
  
 ). The values of λ and h were obtained from non-linear least squares fit. The 
values obtained are shown in Tables 4.7 and 4.8. 
λh Parameter Equation 
IL λ h 103rmsd 
[bmim][PF6] 0.19 13019 1.884 
[hmim][PF6] 0.15 11401 1.489 
Table 4.7: Calculated λ and h Parameters and Root Mean Square Deviation 
T / K 103 exp 103 1
cal 
[bmim][PF6] 
298.15 12.893 12.863 
308.15 18.543 17.242 
318.15 20.285 22.809 
328.15 28.611 29.851 
338.15 41.596 38.740 
[hmim][PF6] 
298.15 26.559 25.999 
308.15 30.485 32.418 
318.15 41.297 40.143 
328.15 51.199 49.452 
338.15 59.083 60.711 
Table 4.8: Comparison of Experimental Data and Calculated Values of Solubility 
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[bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 4.5: Experimental data points (solid points) plotted with trend line (dotted line) 
from calculated values from Buchowski  Equation 
Like the dual parameter equation the Buchowski equation also provided a good fit for the 
experimental data. The good correlation shown here was also observed in work by Ge et al 
(2013), where using the same modelling equation they found a close correlation for the 
solubility of aloe-emodin in five imidazolium based ILs. The results show that such 
correlations may be useful to help in the selection of ILs as fewer data points would be 
needed when selecting an IL to have a specific solubility for a given solute. 
4.2.4 Paracetamol Solubility Conclusions 
Methodology to measure the solubility of paracetamol was established and used to 
successfully measure the equilibrium solubility in [bmim][PF6] and [hmim][PF6]. Both were 
found to be good solvents for paracetamol. However, compared to water both gave lower 
solubilities over the temperature range measured. Given the hydrophobic nature of the ILs 
used here the lower solubility of this polar molecule was expected. However the increased 
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solubility seen for the more hydrophobic [hmim][PF6] would lead to the assumption that 
small differences in impurities could have a significant impact on the solubility and further 
work is required to understand the solvation mechanisms of ILs and the relationship 
between the physical properties of solute and IL. 
While further work is required to determine the solvation mechanisms and interactions it 
was shown that simple fits can be applied to the experimental data to correlate and  predict 
the solubility of these systems. If this is true of most IL-solute systems then this provides a 
useful tool for designing onwards processing steps that involve dissolution. The data 
generated for these two systems also shows that that the solubility does vary with 
temperature meaning that using temperature to generate supersaturated solutions to 
investigate cooling crystallisations is possible. 
4.3 Cooling Crystallisations 
4.3.1 Meta-Stable Zone Width Determination 
Although the MSZW cannot be defined in absolute terms as is it is driven by kinetic rather 
than thermodynamic factors it is important to understand the degree of supersaturation 
that can occur in a particular system giving insight into how easily a system will produce 
crystals. The MSZW was determined for paracetamol in each of the ILs using turbidity to 
detect the cloud point. It can also help determine regions where crystal growth is driven 
either by primary or secondary nucleation followed by crystal growth.  
To determine if there is any significant effect of the rate of cooling, the MSZW was 
investigated at cooling rates of 0.2, 0.5 and 1.0 K.min-1. The obtained nucleation points were 
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plotted with the solubility data obtained in Section 4.2.2 and are shown in Figures 4.6 and 
4.7. 
Equilibrium Solubility ■, cooling rate of 0.2 K.min-1 □, 0.5 K.min-1 ∆ and 1.0 K.min-1 ○ 
Figure 4.6: Paracetamol Equilibrium Solubility and obtained MSZW in [bmim][PF6] 
Equilibrium Solubility ■, cooling rate of 0.2 K.min-1 □, 0.5 K.min-1 ∆ and 1.0 K.min-1 ○ 
Figure 4.7: Paracetamol Equilibrium Solubility and obtained MSZW in [hmim][PF6] 
The MSZWs obtained show that high supersaturation concentrations can be generated. For 
example a supersaturation ratio of ΔS = 3.3 at 333.25 K would be possible indicating that 
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crystals are not readily formed in these systems. However, this does lead to the availability 
of a wide operating window to manipulate using seeded crystallisation.  
The cooling rate was found to have an insignificant impact on the MSZW across the range of 
0.2 to 1.0 K.min-1. The data generated define the operating region for developing a cooling 
crystallisation. 
4.3.2 Primary Nucleated Systems 
Experiments were designed to cross the meta-stable zone width at different levels of 
supersaturation. These scoping experiments investigated the impact of concentration on 
resulting particle formation when the crystals are grown from a primary nucleation event 
and subsequent growth.  
Process Conditions 
Crystallisations were completed to in order to understand the impact of crystallising from 
primary nucleation and subsequent growth. Conditions investigated are displayed in Table 
4.9. 
 
 
 
Table 4.9: Paracetamol Cooling Crystallisation Conditions (non-seeded) 
Where possible the crystallisation was monitored by turbidity; a typical profile is displayed in 
Figure 4.9. In the profile a minimum in the turbidity is observed when dissolution of all the 
powder had occurred. The turbidity remains at this minimum as the solution is cooled until 
Ionic Liquid Concentration 
mg.mL-1 
[bmim][PF6] 44.82 
[bmim][PF6] 54.85 
[bmim][PF6] 70.09 
[hmim][PF6] 15.73 
[hmim][PF6] 30.21 
[hmim][PF6] 69.06 
78 
 
the meta-stable zone width has been crossed and there is a rapid burst of nucleation and the 
material precipitates out of solution causing a dramatic rise in the turbidity. 
 
The plot shows the temperature (red line) increase to 353 K as the input paracetamol is 
dissolved. At this temperature the % turbidity (blue line) reaches zero as there is a clear 
solution. As the solution is cooled to 293 K at 0.2 K.min-1 a sudden rise in the turbidity is 
observed at 325 K due to the spontaneous nucleation of paracetamol. Note the turbidity 
event at 245 K was due to the probe being manual moved to conduct a visual observation. 
Figure 4.8: Typical Turbidity Plot for non-seeded Paracetamol Crystallisation 
Analysis 
Form 
As the MSZW showed, the systems can generate large supersaturations  with the potential 
to crystallise a meta-stable form or to create small particles. There are two well known and 
characterised forms of paracetamol, the monoclinic form I and the orthorhombic form II. A 
third polymorph has also been proposed, which is extremely unstable, rapidly converting to 
one of the other forms. Form II is metastable although can be isolated under the right 
conditions; form I is the most stable form of paracetamol. 
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The form of the resultant crystals was determined by X-Ray Diffraction (XRD) and compared 
to both the calculated XRD pattern and against reference patterns in the literature. 
Reference pattern was obtained from the Cambridge Crystallographic Database (CCDC) are 
displayed in Appendix 2 which were used to confirm that the input material was also the 
monoclinic form I. 
All samples produced XRD patterns consistent with the monoclinic form I material (Nichols, 
1998). An example XRD is shown in Figure 4.9, XRD for the other samples are contained in 
Appendix 2 together with the pattern obtained for the starting material. The monoclinic 
form is most stable as the orthorhombic form; form II is metastable to form I at ambient 
temperature (Burger & Ramberger, 1979). Given the relatively low cooling rate, form I was 
the expected form from these experiments.  
Figure 4.9: Example XRD pattern from [bmim][PF6] cooling crystallisation (blue) with input 
paracetamol material (red) known to be Form I 
0
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To test this, two further crystallisations were completed at a higher cooling rate (10 K.min-1) 
and high concentration 70 mg.mL-1, in each of the ILs. The recovered crystals (data not 
shown) were also found to be form I. 
The precipitated crystals were separated from the ionic liquid by vacuum. Residual IL 
remained on the surface of the crystals as can be seen in the SEM images shown in Table 
4.10. This had the effect of agglomerating the crystals and was particularly seen for the 
smaller and more plate-like particles. As a result XRD patterns obtained for these particles 
had weaker signals and showed signs of preferred orientation, which may have accounted 
for any observed differences in peak intensity. This demonstrates that while ILs can be used 
to precipitate APIs, in order for them to be considered as viable solvents the separation of 
the product from the IL should be the subject of further investigation. 
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Habit 
The particle habit was assessed by optical and Scanning Electron Microscopy (SEM); the 
images are displayed in Tables 4.10 and 4.11. 
 Optical Microscopy Scanning Electron Microscopy 
mg.
mL
-1
 
50X Magnification 100X Magnification 250X Magnification 500X Magnification 
45 
 
    
55 
 
    
69 
 
    
Table 4.10: OM and SEM Images of Paracetamol as crystallised from [bmim][PF6] 
Interestingly, it was found that the habit of the precipitated crystals can be modified through 
changes in both the IL selected and the starting solution concentration. The particle habits 
produced from [bmim][PF6] displayed smaller plate-like particles at the lowest concentration 
(45  mg.mL-1). Triangular prisms were formed when the concentration was increased to 55 
mg.mL-1, while predominantly elongated prism particles were obtained from 69 mg.mL-1 
solutions. 
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Table 4.11: OM and SEM Images of Paracetamol as crystallised from [hmim][PF6] 
When [hmim][PF6] was used at the lowest concentration (16 mg.mL
-1) tetragonal bypyramids 
were formed, increasing the concentration (30 mg.mL-1) small plate particles formed, 
whereas for the highest concentration (69 mg.mL-1) larger more tabular structures were 
produced. 
The crystal habit is dependent on the relative growth rate of the different crystallographic 
faces. The faces that grow rapidly have little or no effect on the particle habit whereas the 
slowest growing faces have most influence. For the crystals produced here, it is likely that 
this change in particle habit is being driven by the change in solution concentration. It has 
been observed in conventional solvents that the growth rate of the crystal faces {001} and 
{110} changes when the supersaturation changes (Finnie, 1999) (Ristic, 2001). At high 
 Optical Microscopy Scanning Electron Microscopy 
mg.
mL-1 
50X Magnification 100X Magnification 250X Magnification 500X Magnification 
16 
    
30 
 
    
69 
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supersaturations (ΔS>1.15), the growth rate of face {110} decreases making these faces 
more dominant, resulting in more elongated crystals at low supersaturations compared to 
those grown at high supersaturations which produced crystals with a flat tabular 
morphology.  
Particle Size 
The particle size of the resultant powders was measured by laser diffraction. A summary of 
the data is shown in Table 4.12. An example of a typical size distribution is shown in Figure 
4.10 with all raw data in Appendix 3. 
 
Figure 4.10: Paracetamol PSD from [hmim][PF6] at 30 mg.ml
-1 
Particle Size 
Experiment 
Number 
Ionic Liquid 
Concentration 
mg.mL-1 
d10 d50 d90 Span 
Distribution 
Description 
1 [bmim][PF6] 44.8 6 23 56 2.2 Multi-Modal 
2 [bmim][PF6] 54.9 144 254 389 1.0 Multi-Modal 
3 [bmim][PF6] 70.1 44 277 621 2.1 Multi-Modal 
4 [hmim][PF6] 15.7 10 37 78 1.8 Tri-Modal 
5 [hmim][PF6] 30.2 7 26 46 1.5 Bi-Modal 
6 [hmim][PF6] 69.1 9 60 124 1.9 Bi-Modal 
Table 4.12: Summary Particle Size Data for Non-Seeded Paracetamol 
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It would be expected that the particle size would decrease as the concentration increases. 
For samples crystallised from [bmim][PF6] and [hmim][PF6] it was found that the least 
concentrated solution produced the smallest particles while the highest concentrated 
solution gave the largest particles. However the experiment completed in [hmim][PF6] at 
30.2 mg.mL-1 did not follow the expected trend. The result highlights that variable nature of 
conducting crystallisations via primary nucleated systems makes controlling the output 
particle size difficult to control from batch to batch. No samples produced mono-modal 
distributions (for example see Figure 4.10). No evidence of attrition was observed from the 
microscopy analysis so the bimodal distribution may result from residual IL that can be 
observed in Figure 4.11. This would account for the size population seen around 3 µm. 
4.3.3 Secondary Nucleated 
In order to control carry out crystallisations under more controlled conditions seed is 
commonly added to supersaturated solutions inducing growth onto the crystals. This is a 
common tactic used in the pharmaceutical industry to control form and habit but in 
particular the particle size of the resultant crystals. 
Process Conditions 
 A set of seeded experiments were conducted at different supersaturation ratios, defined at 
333.15 K as indicated in Table 4.13. The wide MSZW curve at 333.15 K enabled a broad range 
of supersaturations to be investigated before spontaneous crystallisation occurred. 
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Ionic Liquid Concentration 
mg.mL-1 
ΔS at 
 333.15 K 
[bmim][PF6] 38.1 2.0 
[bmim][PF6] 47.4 2.5 
[bmim][PF6] 57.0 3.0 
[hmim][PF6] 35.0 1.25 
[hmim][PF6] 49.0 2.00 
[hmim][PF6] 63.0 2.25 
Table 4.13: Paracetamol Seeded Cooling Crystallisation Conditions 
The crystallisations were also monitored where possible using turbidity. An example of a 
turbidity plot from the experiments is shown in Figure 4.11. 
 
 
 
 
 
 
 
 
 
 
The plot shows the temperature (red line) increase to 365 K as the input paracetamol is 
dissolved. At this temperature the % turbidity (blue line) reaches zero as there is a clear 
solution. Following addition of the seed material at 333.15 K a steady increase is observed as 
material precipitates out of solution growing onto the seed crystals before reaching a 
plateau at equilibrium. Upon cooling there is another inflection in the turbidity as further 
material comes out of solution. 
Figure 4.11: Temperature and Turbidity Profile from [hmim][PF6] at 63 mg.mL
-1 
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Analysis  
Form 
All samples produced diffraction patterns that were consistent with the monoclinic form I 
material. Given that all the non-seeded samples also produced this stable form and that the 
seeds added to the crystallisations were also form I this was an expected result. The XRD 
data for all seeded samples are shown in Appendix 2 while Figure 4.12 shows an example 
XRD pattern together with the input form I material as a reference. 
Figure 4.12: X-Ray Diffraction of Paracetamol from [hmim][PF6] at 35 mg.mL
-1 (Blue Trace) 
with input Paracetamol Form I (Red Trace) 
Particle Habit 
The particle habit was assessed by optical and Scanning Electron Microscopy (SEM) as shown 
in Tables 4.14 and 4.15. 
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Table 4.14: Paracetamol OM and SEM Images from [bmim][PF6] Seeded Crystallisation 
Table 4.15: Paracetamol OM and SEM Images from [hmim][PF6] Seeded Crystallisation 
 Optical Microscopy Scanning Electron Microscopy 
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Samples produced from [bmim][PF6] produced long prisms while the samples grown from 
[hmim][PF6] produced particles with a distinct tetragonal bipyramid habit. Results here 
indicate that it is possible to modify the particle habit in a seeded process through changing 
the alkyl chain length and hence the hydrophobicity of the IL. While these results are 
promising, further investigation would be required to make sure that the changes seen here 
are due to the change in interaction between solute and solvent and not as a result of 
different impurity profiles of the two ILs. 
The impact of ΔS had little impact on the crystal habit at the ranges studied. The 
supersaturation ratios used here were all greater than ΔS>1.25 which are likely to be outside 
the region where changes in habit were observed in aqueous solutions as mentioned 
previously. 
Particle Size 
The particle size of the precipitates was measured by laser diffraction. A selection of the data 
is shown in Table 4.16. An example of a typical size distribution is shown in Figure 4.13 with 
all raw data in Appendix 3. 
Particle Size 
Ionic Liquid 
Supersaturation 
ΔS 
d10 d50 d90 Span 
Distribution 
Description 
[bmim][PF6] 2.0 112 212 323 2.1 Bi-Modal 
[bmim][PF6] 2.5 122 206 329 2.2 Bi-Modal 
[bmim][PF6] 3.0 104 205 349 2.2 Bi-Modal 
[hmim][PF6] 1.25 30 73 121 2.1 Multi-Modal 
[hmim][PF6] 2.00 40 173 314 2.0 Multi-Modal 
[hmim][PF6] 2.25 49 138 228 2.0 Bi-Modal 
Table 4.16: Summary of Paracetamol Particle Size Data from Seeded Crystallisations 
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No trend was observed as the concentration was increased within a given IL. The particle 
size obtained for the [bmim][PF6] produced a very consistent particle size range across the 
concentration range studied each with a bi-modal distribution.  
Figure 4.13: Paracetamol PSD from [bmim][PF6] at ΔS 2.5 
The span of the particle size distributions was consistent, distributions of 2.0 to 2.1 were 
obtained across the range of crystallisations in [bmim][PF6] and [hmim][PF6], while for the 
[hmim][PF6] samples, although the span of the size distributions was consistent and similar 
to those obtained from [bmim][PF6], the particle size obtained was not consistent and varied 
significantly between runs. The particle size obtained was also generally smaller from 
[hmim][PF6] to those obtained from [bmim][PF6]. 
4.3.4 Extension to Other ILs 
The cooling results above show that ILs can be used as media to crystallise paracetamol. One 
of the main potential benefits of ILs is the range of ILs that potentially could be used. This 
section of the practical work aims to extend the above practical work by screening other ILs 
that may be suitable as crystallisation media. For this work it was decided to concentrate on 
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the same cation and vary the anion. The criteria used for selection are detailed in Section 
3.2.2 methods section, such that the ILs were liquids at room temperature, the purity was 
>95% and the cost was <£2 per g.  The ILs used for this screening study are outlined below in 
Table 4.17. To carry out the screen the solubility was measured at three temperatures and 
potential candidates then selected for further evaluation. 
Temperature  K [bmim][BF4] 
mg.mL-1 
[bmim][NTf2] 
mg.mL-1 
[bmim][CH3COO] 
mg.mL-1 
[bmim][C8H17OSO3] 
mg.mL-1 
298.15 68.9 8.4 >277.0 >287.7 
328.15 124.9 15.4 Not Measured Not Measured 
358.15 194.8 32.2 Not Measured Not Measured 
Note: the biggest error measured between duplicate results was 4 mg.mL-1 
Table 4.17: Paracetamol Solubility Measured during Screening Work 
It was found that paracetamol was highly soluble in the ILs [bmim][CH3COO] and 
[bmim][C8H17OSO3] with a measured solubility of >277 mg.mL
-1  were seen at 298.15 K. The 
solutions that were formed were also extremely viscous which could prove challenging to 
agitate and separate the liquid from any crystallised product. The ILs [bmim][BF4] and 
[bmim][NTf2] were selected for further evaluation and the dual parameter equation 
assessed in Section 4.2.3 was used to correlate the solubility data. The results from the 
parameters used with corresponding root mean square deviation are shown in Table 4.18 
followed by the calculated values in Table 4.19 with the plotted data in Figure 4.14. 
IL A B 103rmsd 
[bmim][BF4] 2.919 -1573.7 3.161 
[bmim][NTf2] 3.791 2268.2 2.658 
Table 4.18: Paracetamol Extension Calculated Dual Equation Parameters 
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 [bmim][BF4] [bmim][NTf2] 
Temperature 
K 
103 exp 103 cal 103 exp 103 cal 
298.15 93.395 94.54 22.772 22.02 
328.15 157.358 153.18 40.971 44.13 
358.15 225.560 228.90 82.002 78.74 
Table 4.19: Paracetamol Extension Calculated Solubility Values 
[bmim][BF4]■ and [bmim][NTf2]▲ 
Figure 4.14: Paracetamol Extension Experimental Data (solid points) with Trend Line from 
Dual Parameter (dotted line) 
Again a good correlation was obtained using this method. The solubility curves produced 
from this correlation were then used as a basis for preliminary crystallisation studies from 
these ILs. 
Two cooling crystallisations were performed in each IL, a non-seeded crystallisation using 
the concentration at 358.15 K followed by a seeded crystallisation at the same 
concentration. As the metastable zone width has not been fully established for these 
systems the seed point used was determined using the data from the estimated solubility 
curve and the point of nucleation of the non-seeded crystallisation. 
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Analysis 
Form 
Samples all samples from these crystallisations produced material that was consistent with 
the stable form I material. The obtained diffraction patterns are shown in Appendix 2 with 
an example shown in Figure 4.15. 
 
 
 
 
 
 
Figure 4.15: Paracetamol XRD from non-seeded [bmim][NTf2] Crystallisation 
 
Particle Habit 
Optical and scanning electron microscopy was carried on cooling crystallisation samples, 
images are shown in Table 4.20 
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 Table 4.20: Paracetamol Images from cooling crystallisation extension experiments 
There have been numerous studies in the literature studying the crystallisation of 
paracetamol from conventional solvents. The work by Finnie et al (1999) where the habit 
changes were described used aqueous solutions to conduct their studies and produced 
particles ranging from plate material to larger more tabular structures at high saturations. 
This larger tabular particle habit was produced by Yu et al (2005) from aqueous systems 
using acetone as an anti-solvent. These two habits were also produced when crystallised 
from ethanol (Ristic et al, 2001) and from benzyl alcohol (Nichols and Frampton, 1998). In a 
study by Lee et al (2006) paracetamol was crystallised from thirteen pure solvents. Their 
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study found that plate-like crystals were formed from benzyl alcohol, n-butyl alcohol and 
water. The solvents acetonitrile, 1,4 dioxane, isopropyl alcohol, methanol, methyl ethyl 
ketone, and tetrahydrofuran gave prism like habits.  
Interestingly no evidence of cubic paracetamol particles was found, like those formed from 
[bmim][BF4]. In order to determine which faces are being influenced from this IL further 
work will be needed to index the crystal. 
4.4 Summary 
In order to firstly understand if the API paracetamol can be crystallised from ionic liquids a 
detailed study was conducted using the [bmim][PF6] and [hmim][PF6]. The MSZW 
determined for these systems showed that, at small scale, large supersaturations could be 
generated, increasing the potential risk of meta-stable forms being produced and recovered. 
Another feature of the MSZW obtained for these systems was that at low temperatures the 
increased viscosity of the IL may slow down the crystallisation process as this is kinetically 
driven. Despite the wide meta-stable zone width the obtained results were very consistent, 
even at a range of cooling rates, whereas for conventional crystallisations it would be 
expected that the obtained MSZW would be much more variable.  
A series of crystallisations designed to cross the MSZW at a range of increasing 
concentrations was carried out to determine the impact on the form, habit and size of the 
crystallised particles. Despite the large supersaturations that were generated, the systems all 
crystallised as the stable monoclinic form I. The particle habit produced from these 
crystallisation showed that different habits could be produced by changing both the length 
of the alkyl chain length and the concentration of the crystallising solution. The particle size 
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did not follow the expected trend, with large particles formed from highly concentrated 
solutions, which indicates a significant amount of growth occurring in the systems following 
the spontaneous nucleation, and the much increased viscosity of ILs compared to 
conventional molecular solvents may be the reason for this. 
Crystallisations were also conducted using seed to act as secondary nuclei. These systems 
generally behaved as expected with much larger particles being produced compared to 
primary nucleated crystallisations. Variation of the supersaturation ratio at point of seeding 
had little impact on the habit of the particles produced.  
The impact of changing the anion was assessed by completing a series of scoping 
experiments on different ILs. The results show that the different morphologies can be 
produced while still maintaining the most stable form. 
Some practical issues with working with ionic liquids were encountered during the studies. 
One of these was that the viscosity of the ILs used, particularly at isolation temperatures, 
makes it difficult to obtain reliable solubility data and MSZW data. Where the API is freely 
soluble, the sample becomes so viscous that in some instances it can form a gel that cannot 
be sufficiently agitated. Secondary to this is that high viscosity can cause issues during the 
separation of the crystals from the IL liquor. 
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CHAPTER 5: STUDIES WITH IBUPROFEN 
5.1 Introduction 
This chapter is focussed on the experimental work completed on ibuprofen. Starting first by 
outlining the methodology used to determine the solubility of ibuprofen in the ILs 
[bmim][PF6] and [hmim][PF6], the results were then assessed using solubility correlations to 
understand if these models could be applicable to such systems. 
Using these unique solvents a series of cooling crystallisations were designed and 
completed. The Meta-Stable Zone Width (MSZW) was established and combined with the 
solubility data to design a series of cooling crystallisations. The crystallisations assessed the 
impact of nucleation mechanism and concentration on the crystal form, habit and size of the 
resultant crystals.  
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5.2 Solubility 
5.2.1 Validation of Solubility Method – Solubility in Water 
Before the solubility of Ibuprofen in ILs was measured the solubility was measured in water 
to validate that the method used in this work was fit for purpose. Solubility data were 
determined between 298.15 K and 338.15 K in 10 K increments. For each measurement the 
overall mean from the three experiments, plus or minus the standard error of the mean, 
were calculated for both the absorbance and solubility. 
A summary of the data is shown below in Table 5.1. The raw data obtained from the UV 
spectrophotometer with corresponding solubility data in mg solute per mL water can be 
found in Appendix 4. 
Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
298.15 0.213 ± 0.008 0.124 ± 0.004 
308.15 0.313 ± 0.036 0.179 ± 0.020 
318.15 0.489 ± 0.140 0.276 ± 0.077 
328.15 0.669 ± 0.126 0.376 ± 0.070 
338.15 0.935 ± 0.148 0.523 ± 0.082 
Table 5.1: Solubility of Ibuprofen in Water 
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
The US Pharmacopeia lists Ibuprofen having a solubility less than 1 mg.mL-1 at 298.15 K, 
meaning that it is only very slightly soluble in water at room temperature. This definition 
matches the data measured here with solubilities in the range of 0.124 mg.mL-1 to 0.523 
mg.mL-1 determined across the temperature range. Ibuprofen only has one polar group, the 
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carboxylic acid functional group making it less soluble in polar solvents like water compared 
to paracetamol. 
The data was were plotted against previously published data (Potthast, 2005), (Garzon, 
2004), (Higgins, 2004) and (Stippler, 2004) shown in Figure 5.1. 
 
 
Figure 5.1: Solubility Data in Water as a Function of Temperature for Ibuprofen. 
The data published for Ibuprofen are more variable as the solubility of Ibuprofen varies with 
pH; also the low solubility (<3.5 mg.mL-1) would be sensitive to techniques used. The data in 
this work were obtained using analytical grade water (pH 7.4). While the data measured in 
this work fit within the range of the available data it is clear that the measured solubility for 
ibuprofen is highly dependent on the conditions used for the study. 
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5.2.2 Solubility in Ionic Liquids 
Using the same method, the solubility of ibuprofen was determine in the ILs [bmim][PF6] and 
[hmim][PF6] across the temperature range 298.15 K to 338.15 K at 10 K increments. A 
summary of the data is shown below in tables 5.2 and 5.3 for [bmim][PF6] and [hmim][PF6] 
respectively. The raw data obtained from the UV spectrophotometer with corresponding 
solubility data in mg solute per mL water can be found in Appendix 4.  
Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
 298.15 0.706 ± 0.014 12.18 ± 0.27 
308.15 1.131 ± 0.027 20.27 ± 0.48 
318.15 1.720 ± 0.068 31.53 ± 1.29 
328.15 2.685 ± 0.024 36.45 ± 0.35 
338.15 2.888 ± 0.009 56.81 ± 0.19 
Table 5.2: Solubility of Ibuprofen in [bmim][PF6] from T = 298.15 K to 338.15 K 
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
Temperature 
K 
Absorbance 
∑abs (     
Solubility 
mg.mL-1 
298.15 1.254 ± 0.095 26.38 ± 2.08 
308.15 1.749 ± 0.113 37.20 ± 2.47 
318.15 2.139 ± 0.113 50.76 ± 2.67 
328.15a 2.005 ± 0.033 65.88 ± 1.08 
338.15a 1.371 ± 0.048 120.41 ± 4.15 
a 
The absorbance values are out of line for 328.15 K and 338.15 K due to additional dilution of the samples. 
Table 5.3: Solubility of Ibuprofen in [hmim][PF6] from T = 298.15 K to 338.15 K,  
where solubility is the overall mean from three independent experiments ± the standard 
error of the mean 
Both ILs were found to be good solvents with solubility values of 12.18 mg.ml-1 to 56.81 
mg.mL-1 obtained for [bmim][PF6] and 26.38 mg.mL
-1 to 120.41 mg.mL-1 for [hmim][PF6] 
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across the temperature range studied. This would rank ibuprofen as ranging from sparingly 
soluble to soluble in [bmim][PF6] and sparingly soluble to freely soluble in [hmim][PF6]. The 
data was plotted together with the water solubility data obtained previously in Figure 5.2. 
water ♦, [bmim][PF6] ■ and [hmim][PF6]▲. Solubility as a function of temperature for 
Ibuprofen. Each point represents the overall mean from three independent experiments ± 
the standard error of the mean 
Figure 5.2: Ibuprofen Equilibrium Solubility Data 
The solubility was greater in [hmim][PF6] than [bmim][PF6]. Based on the structure of the 
molecule this result would be expected  as ibuprofen is likely to favour solvents of lower 
relative polarity. 
The solubility data at 328.15 K and 338.15 K for [bmim][PF6] should be treated with a degree 
of caution as there was evidence of degradation observed through the onset of colour 
change which was not observed in either water or [hmim][PF6]. The water content was 
measured by Karl Fischer and found to be 0.15 % (w/w). It is known that in the presence of 
water ILs containing fluorinated species such as [PF6] can produce hydrogen fluoride, 
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especially at elevated temperatures, so catalysing the degradation of the ibuprofen. Caution 
should be taken when working with this anion at elevated temperatures ensuring that the 
ILs are dry and exposure to the atmosphere is kept to a minimum. It should be noted that 
the water content of [hmim][PF6] was measured at 0.05 % (w/w). 
5.2.3 Modelling Ibuprofen Solubility Data in ILs 
van’t Hoff plots 
If the solvent and solute are assumed to form an ideal solution then dissolution enthalpy 
(ΔHd) and entropy (ΔSd) can be predicted from the van’t Hoff equation (Equation 2.1). The 
van’t Hoff plots are shown in Figure 5.3 with extrapolated values in Table 5.4. 
Water ♦, [bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 5.3: van’t Hoff plot of Ibuprofen 
Solvent Water [bmim][PF6] [hmim][PF6] 
ΔHd  
kJ.mol-1 
30.38 20.27 26.86 
ΔSd  
 J.mol-1.K-1 
6.79 67.13 65.15 
Table 5.4: Dissolution Enthalpy and Entropy Values from van’t Hoff Plot 
-14 
-12 
-10 
-8 
-6 
-4 
-2 
0 
0.0029 0.00295 0.003 0.00305 0.0031 0.00315 0.0032 0.00325 0.0033 0.00335 0.0034 
ln
x 
1/T 
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In each case values of ΔHd  > 0 and thus the solvation process is endothermic, indicating that 
the interactions between ibuprofen and the solvents are not strong enough to break down 
the energy of attraction of the ibuprofen molecules with each other and the electrostatic 
interactions of the IL cation and anion. Positive values of ΔSd were also obtained indicating 
that the Ibuprofen-solvent system became increasingly disordered as temperature was 
increased. 
Dual Parameter 
A simplified dual parameter equation, (        
 
 
  , was used to determine if the 
solubility results could be fitted in this way. The values of A and B were obtained by least 
squares fit from the experimental data.  
The calculated parameters are displayed in Table 5.5 with the root mean square deviation. 
The dual parameter and calculated values are compared together in Table 5.6. The 
experimental data and calculated data were plotted together in Figure 5.4. 
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Dual Parameter Equation 
IL A B 103rmsd 
[bmim][PF6] 7.929 -3568.8 2.950 
[hmim][PF6] 7.852 -3325.2 9.042 
Table 5.5: Calculated A and B Parameters and root mean square deviation 
T / °K 103 exp 103 1
cal 
[bmim][PF6] 
298.15 16.502 17.584 
308.15 27.165 25.931 
318.15 41.627 37.318 
328.15 47.812 52.526 
338.15 72.580 72.452 
[hmim][PF6] 
298.15 38.396 36.854 
308.15 53.304 52.926 
318.15 71.348 74.297 
328.15 90.674 102.164 
338.15 154.157 137.860 
Table 5.6: Comparison of experimental data and fitted values of solubility 
[bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 5.4: Experimental data points (solid points) and fitted data (dotted line) 
The obtained fit  from the dual parameter equation is in good agreement for the [bmim][PF6] 
system. However, more deviation was observed in the [hmim][PF6]–ibuprofen system 
especially at the higher temperatures. The calculated data could still be used to describe the 
0.0 
20.0 
40.0 
60.0 
80.0 
100.0 
120.0 
140.0 
160.0 
180.0 
295 300 305 310 315 320 325 330 335 340 345 
1
0
3
x 
Temperature K  
105 
 
trend of solubility but may not be an accurate predictor at high temperatures; the possibility 
of degradation should also be considered. 
Buchowski  Equation 
The relationship between mole fraction solubility and temperature on the solid-liquid phase 
equilibrium was also assessed using the λh (Buchowski) equation (      
   
 
  
     
 
  
  
 
  
 ). The values of λ and h were obtained from non-linear least squares fit.  
λh Parameter Equation 
IL λ h 103rmsd 
[bmim][PF6] 0.85 4187 2.975 
[hmim][PF6] 1.87 1931 8.493 
Table 5.7: Calculated λ and h Parameters and root mean square deviation 
T /K 103 exp 103 1
cal 
[bmim][PF6] 
298.15 16.502 17.641 
308.15 27.165 25.993 
318.15 41.627 37.402 
328.15 47.627 52.680 
338.15 72.580 72.784 
[hmim][PF6] 
298.15 38.396 35.720 
308.15 53.304 52.475 
318.15 71.348 74.998 
328.15 90.674 104.445 
338.15 154.157 141.916 
Table 5.8: Comparison of experimental data and calculated values of solubility 
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[bmim][PF6] ■ and [hmim][PF6]▲ 
Figure 5.5: Experimental data points (solid points) plotted with trend line (dotted line) 
from calculated values from Buchowski  Equation 
A reasonable correlation was found using both the dual parameter and the Buchowski 
equation with both approaches giving very similar fits to one another. The errors associated 
with the fit are greater than was observed for the studies in paracetamol due to the greater 
deviation between correlated data and experimental data at high temperatures, particularly 
for [hmim][PF6] where larger errors were recorded for the high temperature data (cf. 
comment on degradation in dual parameter discussion). 
5.2.4 Ibuprofen Solubility Conclusions 
Methodology to measure the solubility of Ibuprofen was established and used to 
successfully measure the equilibrium solubility in [bmim][PF6] and [hmim][PF6]. The 
methodology highlighted the care needed when conducting such measurements as small 
changes in pH can have a significant impact. Compared to water, ILs were found to be good 
solvents for ibuprofen over the temperature range measured. Ibuprofen is more 
hydrophobic than paracetamol, meaning that it has more favourable solubility in the 
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hydrophobic ILs. The models used showed good correlation at lower temperatures. However 
for high temperatures where the solubility is greater, the errors between the experimental 
and calculated were more significant. 
The data generated for these two systems also shows that that the solubility does vary with 
temperature, meaning that using temperature to generate supersaturated solutions to 
investigate cooling crystallisations is possible. 
5.3 Cooling Crystallisations 
5.3.1 Meta-Stable Zone Width Determination 
Using the same methodology used for during the Paracetamol investigation (see Chapter 4 
Section 4.3.1) the MSZW was defined and the corresponding data shown in Figures 5.6 and 
5.7. 
Equilibrium Solubility ■, cooling rate of 0.2 K.min-1 □, 0.5 K.min-1 ∆ and 1.0 K.min-1 ○ 
Figure 5.6: Ibuprofen Equilibrium Solubility and obtained MSZW in [bmim][PF6] 
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Equilibrium Solubility ■, cooling rate of 0.2 K.min-1 □, 0.5 K.min-1 ∆ and 1.0 K.min-1 ○ 
Figure 5.7: Ibuprofen Equilibrium Solubility and obtained MSZW in [hmim][PF6] 
The MSZWs obtained here are extremely high, especially in the case of [hmim][PF6]. The 
MSZWs obtained show that high supersaturation concentrations can be generated, for 
example a supersaturation ratio of ΔS = 5.8 at 293.15 K would be possible indicating that 
crystals are not readily formed in these systems. However, this does lead to the availability 
of a wide operating window to manipulate using seeded crystallisation.  
The cooling rate was found to have an insignificant impact on the MSZW across the range of 
0.2 to 1.0 K.min-1. The data generated define the operating region for developing a cooling 
crystallisation. 
5.3.2 Primary Nucleated Systems 
The unseeded experiments were designed to cross the meta-stable zone width at different 
levels of supersaturation. These scoping experiments investigated the impact of 
concentration on resulting particle formation when the crystals are grown from a primary 
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nucleation event. Following these experiments a set of seeded experiments was conducted 
at different supersaturation ratios. 
5.3.2.1 Process Conditions 
A number of unseeded crystallisations were completed to in order to understand the impact 
of crystallising from primary nucleation and subsequent growth. Conditions investigated are 
displayed in Table 5.9. 
 
 
 
Table 5.9: Ibuprofen Cooling Crystallisation Conditions (non-seeded) 
Where possible the crystallisation was monitored by turbidity, a typical profile being 
displayed in Figure 5.8. In the profile a minimum in the turbidity is observed when 
dissolution of all the powder had occurred. The turbidity remains at this minimum as the 
solution is cooled until the meta-stable zone width has been crossed and there is a rapid 
burst of nucleation and the material precipitates out of solution causing a rise in the 
turbidity.  
Ionic Liquid Concentration 
mg.mL-1 
[bmim][PF6] 28 
[bmim][PF6] 57 
[bmim][PF6] 83 
[hmim][PF6] 79 
[hmim][PF6] 120 
[hmim][PF6] 155 
110 
 
 
The plot shows the temperature (red line) 355 K as the input ibuprofen is dissolved. At this 
temperature the % turbidity (blue line) is zero as it is a clear solution. As the solution is 
cooled to 293 K at 0.2 K.min-1 a sudden rise in the turbidity is observed at 325 K due to 
spontaneous nucleation. 
Figure 5.8: Typical Turbidity Plot for non-seeded Ibuprofen Crystallisation 
 Analysis 
Form 
As the MSZW showed, the systems can generate large supersaturations, increasing the 
potential either to crystallise a meta-stable form. However there is only one well known and 
characterised form of ibuprofen; another form has been proposed in the literature but is 
very unlikely to form. 
The form of the resultant crystals was determined by X-Ray Diffraction (XRD) and compared 
to both the calculated XRD pattern and against published literature. All samples produced 
XRD patterns consistent with the form I material and are shown in Appendix 5 with an 
example trace shown in Figure 5.9. 
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Figure 5.9: Example XRD pattern from [hmim][PF6] cooling crystallisation (blue) with input 
ibuprofen material (red) known to be Form I 
As was found with the paracetamol work, when the precipitated crystals were separated 
from the IL, residual liquid remained on the surface of the crystals as can be seen in the SEM 
images shown in Table 5.8 and 5.9. This had the effect of agglomerating the crystals and was 
particularly seen for the smaller and more plate-like particles. As a result XRD patterns 
obtained for these particles had weaker signals and showed signs of preferred orientation, 
which may have accounted for any observed differences in peak intensity. This demonstrates 
that while ILs can be used to precipitate APIs, in order for them to be considered as viable 
solvents the separation of the product from the IL should be the subject of further 
investigation. 
Habit 
The particle habit was assessed by optical microscopy and SEM; images for the obtained 
powders are shown in Tables 5.10 and 5.11. 
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 Optical Microscopy SEM 
mg.
mL
-1
 
50X Magnification 100X Magnification 250X  Magnification 500X  Magnification 
28 
    
57 
    
83 
    
Table 5.10: OM and SEM images of Ibuprofen from [bmim][PF6] 
 Optical Microscopy SEM 
mg 
.mL
-1
 
50X Magnification 100X Magnification 250X  Magnification 500X  Magnification 
79 
    
120 
    
155 
    
Table 5.11: OM and SEM images of Ibuprofen from [hmim][PF6] 
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The predominant habit produced was acicular or small plate-like particles, though some 
larger plates were observed in the highest concentrated sample. Unlike paracetamol it was 
found that concentration and modification of the alkyl chain length from butyl to hexyl had 
little impact on the habit produced. 
Particle Size 
The particle size of the resultant powders was measured by laser diffraction. A summary of 
the data is shown in Table 5.12. An example of a typical size distribution is shown in Figure 
5.10 with all raw data in Appendix 6. 
 
Figure 5.10: Ibuprofen PSD from [hmim][PF6] at 120 mg.ml
-1 
Particle Size 
Ionic Liquid 
Concentration 
mg.mL-1 
d10 d50 d90 Span 
Distribution 
Description 
[bmim][PF6] 28 4 17 44 2.4 Tri-Modal 
[bmim][PF6] 57 9 24 50 1.9 Tri-Modal 
[bmim][PF6] 83 15 36 79 1.8 Bi-Modal 
[hmim][PF6] 79 5 15 34 1.9 Tri -Modal 
[hmim][PF6] 120 16 32 58 1.3 Tri -Modal 
[hmim][PF6] 155 11 27 56 1.7 Tri-Modal 
Table 5.12: Summary Particle Size Data for Ibuprofen 
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Particle data for the experiments showed no obvious trends. It would be expected that the 
particle size would decrease as the concentration increases. For samples crystallised from 
[bmim][PF6] and [hmim][PF6], it was found that the least concentrated solution produced the 
smallest particles while the highest concentrated solution gave the largest particles. These 
data are similar to the particle size observations for the paracetamol work. The highest 
concentrated samples cross the MSZW much earlier, these crystals are then able to go 
through a significant growth phase as the crystallisation slowly cools down to ambient 
temperature. For the lowest solubility samples, the temperature at which nucleation occurs 
is much closer to the isolation temperature, meaning that there is less material (and time) 
for the crystals to undergo as much growth. 
5.3.3 Secondary Nucleated Systems 
In order to carry out crystallisations under more controlled conditions seed is commonly 
added to supersaturated solutions inducing growth onto the crystals. This is a common tactic 
used in the pharmaceutical industry to control form and habit but in particular the particle 
size of the resultant crystals.  
Process Conditions 
A set of seeded experiments were conducted at different supersaturation ratios, defined at 
333.15 K as indicated in Table 5.13. The wide MSZW curve at 333.15 K enabled a broad range 
of supersaturations to be investigated before spontaneous crystallisation occurred.  
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Ionic Liquid Concentration 
mg.mL-1 
ΔS at 
 333.15 K 
[bmim][PF6] 61 1.28 
[bmim][PF6] 72 1.50 
[bmim][PF6] 84 1.75 
[hmim][PF6] 113 1.25 
[hmim][PF6] 136 1.51 
[hmim][PF6] 158 1.75 
Table 5.13 : Ibuprofen Seeded Cooling Crystallisation Conditions 
Reactions here were also monitored where possible using turbidity (refer to Chapter 4, 
Figure 4.11 for details of typical profile). Following addition of the seed material at 333.15 K, 
a steady increase is observed as material precipitates out of solution, growing onto the seed 
crystals. 
Analysis 
Form 
All samples produced XRD patterns that were consistent with form I material. Given that all 
the non-seeded samples also produced this stable form and that the seeds added to the 
crystallisations were also form I this was an expected result. The raw data for all seeded 
samples are shown in Appendix 5 while Figure 5.11 shows an example. 
 
116 
 
 
Figure 5.11: X-Ray Diffraction of Ibuprofen from [bmim][PF6] (Blue Trace) with input 
Ibuprofen Form I (Red Trace) 
Particle Habit 
The particle habit was assessed by optical microscopy and SEM, as shown in Tables 5.14 and 
5.15. ΔS had little impact on the crystal habit at the ranges studied, with plate-like particles 
forming in all the samples. Compared to the primary nucleated systems the particles were 
less acicular showing that growth onto the seed crystals had occurred. 
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Table 5.14: Ibuprofen OM Images of Ibuprofen from [bmim][PF6] 
Table 5.15: Ibuprofen OM and SEM Images of Ibuprofen from [hmim][PF6] 
 Optical Microscopy SEM 
ΔS 50X Magnification 100X Magnification 250X  Magnification 500X  Magnification 
1.28 
    
1.50 
    
1.75 
    
 Optical Microscopy Scanning Electron Microscopy 
ΔS 50X Magnification 100X Magnification 250X Magnification 500X Magnification 
1.25 
    
1.51 
    
1.75 
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Comparison to organic solvents 
Comparing the habits produced here to those obtained from other published data on 
conventional solvents it was observed that the majority of solvent systems produced thin 
plates or acicular habits. Rasenack and Muller (2002) crystallised ibuprofen using a number 
of techniques by using water as an anti-solvent. They found that material crystallised using a 
similar cooling crystallisation process, forming similar needle-like particles from acetone, 
diethyl ether and hexane. A change in habit was seen for samples crystallised from a cooling 
dichloromethane solution, where more cubic particles were observed. Cano et al (2001) 
conducted crystallisation studies into the impact of ethanol and ethyl acetate on the growth 
of single crystals. They found that the growth rate of the faces in ethanol was of the same 
order of magnitude, resulting in a relatively isomeric crystal whereas the crystals grown from 
ethyl acetate resulted in thin elongated particles, indicating that the ethyl acetate does 
impact the growth of the (1 0 0) face. When looking at the molecular arrangement of this 
face it is composed of successive layers that exhibit either polar or non-polar functional 
groups. The polar carboxylic acid groups project out from the surface, allowing them to form 
strong hydrogen bonds. The imidazolium cation can hydrogen bond from the C2 position, 
meaning that this is also likely to interact with the (1 0 0) face, leading to the acicular 
material. 
Particle Size 
The particle size of the precipitates was measured by laser diffraction; a selection of the data 
are shown in Table 5.16. An example of a typical size distribution is shown in Figure 5.12 
with all raw data in Appendix 6.  
119 
 
 
 
 
 
Table 5.16: Summary of Ibuprofen Particle Size Data from Seeded Crystallisations 
The particle sizes obtained from the seeded crystallisation studies are larger than those 
produced from the primary nucleated systems. A decrease in the particle size was observed 
as supersaturation was increased. This was coupled with the either a bi-modal, tri-modal or 
multimodal distribution indicating that two modes of nucleation are occurring in the system, 
with growth of the crystals and spontaneous nucleation, or that the particles produced from 
the more highly concentrated samples are more prone to attrition by breaking into smaller 
particles. The possibility that remaining IL on the surface contributes to the size distribution 
should also be considered (cf. as considered in Section 4.3.2). 
 
Figure 5.12: Ibuprofen PSD from [bmim][PF6] at ΔS 1.5 
Particle Size 
Ionic Liquid ΔS d10 d50 d90 Span 
Distribution 
Description 
[bmim][PF6] 1.28 27 79 185 2.0 Bi-Modal 
[bmim][PF6] 1.50 17 40 88 1.8 Multi-Modal 
[bmim][PF6] 1.75 11 29 67 1.9 Multi-Modal 
[hmim][PF6] 1.25 28 133 352 2.4 Tri-Modal 
[hmim][PF6] 1.51 24 62 146 2.0 Bi-Modal 
[hmim][PF6] 1.75 14 40 120 2.7 Tri-Modal 
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5.4 Summary 
It has been shown that ibuprofen can be successfully crystallised from [hmim][PF6] and 
[bmim][PF6] using cooling crystallisation. However, unlike paracetamol there was no change 
in the particle habit resulting from changing either the IL or the concentration, as it is likely 
that the cation may interact with the (1 0 0) resulting in elongated particles. No significant 
benefit to crystallising from the ILs used here or those selected as part of the test set over 
conventional organic solvents could be identified so no further investigation was carried out. 
It is possible that other ILs containing different cations may be selected to produce a more 
isomeric crystal but fundamental changes in habit are not anticipated. 
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CHAPTER 6: STUDIES WITH FLUFENAMIC ACID 
6.1 Introduction 
This chapter is focussed on the experimental work completed on flufenamic acid, which is a 
potent anti-inflammatory API used in the treatment of osteoarthritis, rheumatoid arthritis 
and other painful musculosketal illnesses. Flufenamic acid is known to be highly 
polymorphic with eight polymorphs having been reported in the literature. The screening 
methodology established in previous chapters was applied to assess if ILs could be used to 
crystallise this compound and whether the polymorphic form of the API could be controlled 
through choice of IL. Where possible the results are compared to literature data for 
conventional organic solvents. 
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6.2 Solubility 
6.2.1 Solubility of Flufenamic Acid in Water and ILs 
Using the screening methods established during the studies on paracetamol and ibuprofen, 
the same methodology was applied to Flufenamic acid. Where practically possible a three 
point solubility curve was established in each of the chosen IL test sets. 
In order to determine if the method and materials used gave a suitable measurement of the 
solubility, the solubility was measured in water and compared to literature values at 298.15 
K. Other data at elevated temperatures could not be found, hence the single point 
comparison for this compound as shown in Table 6.1. 
Temperature 
K 
Solubility a 
mg.mL-1 
Solubility b 
mg.mL-1 
298.15 0.01 ± 0.018 0.01 
Table 6.1: Flufenamic Acid Solubility in H2O for this Work
a and Domańska et alb 
The measured solubility at 298.15 K was in good agreement with the work of Domańska et 
al (2011) giving confidence that suitably accurate results could be obtained. Solubility data 
were then determined as 298.15 K, 328.15 K and 358.15 K for each of the ILs selected as the 
test set for this study. For each measurement, the mean from duplicate experiments plus or 
minus the standard error of the mean were calculated. This is intended as a screening 
method for establishing fit for purpose data that would allow for suitable solvent selection. 
It is recognised that if a crystallisation process was to be developed further then further 
more detailed studies would be required to fully establish equilibrium solubility. The 
solubility results are shown in Table 6.2 and Figure 6.1. 
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Temperature  
K 
[bmim][BF4] 
mg.mL-1 
[bmim][NTf2] 
mg.mL-1 
[bmim][CH3COO] 
mg.mL-1 
[bmim][C8H17OSO3] 
mg.mL-1 
[bmim][PF6] 
mg.mL-1 
[hmim][PF6] 
mg.mL-1 
298.15 7.94 ± 0.03  2.16 ± 0.02 130.49 ± 0.92 100.97 ± 1.61 27.55 ± 1.08 3.17 ± 0.01 
328.15 14.49 ± 0.88 3.50 ± 0.03 Not Measured Not Measured 34.60 ± 0.39 8.54 ± 1.63 
358.15 24.66 ± 0.19 7.75 ± 1.22 Not Measured Not Measured 42.90 ± 0.20 
13.67 ± 
0.48 
Table 6.2: Solubility Results Screen for Flufenamic Acid 
[bmim][BF4] ♦, [bmim][PF6] ■, [hmim][PF6] ▲ and [bmim][NTf2] ● 
Figure 6.1: Solubility Data for Flufenamic Acid obtained from 298.15 K to 358.15 K 
No further measurements beyond 298.15 K were obtained for the samples from 
[bmim][CH3OO] and [bmim][C8H17OSO3] for two reasons. Firstly, the solubility at the modest 
temperature of 298.15 K meant that large amounts of flufenamic acid would be needed to 
develop a crystallisation as large amounts of material would remain in solution on isolation. 
Secondly, the large amount of dissolved material also meant that the solutions were highly 
viscous and formed a gel-like consistency which makes separation more problematic. 
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A range of solubilities was observed from the IL test set. For the anions test, solubilities fell 
between those published in the literature for water and alcohols (Domańska et al 2011) 
with solubilities between 2.16 mg.mL-1 and 130.49 mg.mL-1 measured at 298.15 K. The anion 
was found to have a significant impact on the solubility of Flufenamic Acid. 
When comparing the two [PF6]
- containing ILs it was found that increasing the alkyl chain 
length from butyl to hexyl and hence increasing the hydrophobicity caused the solubility to 
decrease. The same trend is observed in the organic solvents ethanol and 1-octanol. At 
298.15 K ,using the same [bmim] cation the solubility was found to follow the following 
order NTf2 < BF4 < PF6 < C8H17OSO3 < CH3COO. 
Before the solubility data are reported it is necessary to scrutinise the reliability of the 
obtained data for this compound. The compound is known to be highly polymorphic and as 
solubility is intrinsically linked to the polymorphic form it is necessary to determine if any 
polymorphic changes were occurring during the solubility determination. An example of the 
XRD trace for [bmim][BF4] is shown below in Figure 6.2; the remaining XRD traces are shown 
in Appendix 7. 
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Figure 6.2: XRD patterns for slurry samples in [bmim][BF4] at 298.15 K (red), 328.15 K 
(blue) and 358.15 K (green). 
For all cases a change in the polymorphic form of the slurry samples was measured across 
the temperature range investigated. Hu et al (2005) found that Flufenamic Acid has a form 
transition from form III to form I around 318.15 K which accounts for the change in form 
seen here between 298.15 K and 328.15 K. 
The solubility is intrinsically linked to how the unit cell packs. The impact of form on the 
solubility will be dependent on the compound and the specific forms being compared. 
Pudipeddi and Serajuddin (2005) compared the ratio of different forms of drug substances 
and show that, in general, the ratio is typically less than 2 fold. In the same research they 
determined the ratio of flufenamic Acid polymorphs using calculated ideal solubilites and 
using the Hoffman equation showed that the ratios at 303.15 K to be <1.9 but is unclear 
which forms are being compared. 
The collected solubility data therefore cannot be considered as true equilibrium solubility 
data due to the change in form across the temperature range studied and as such no 
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modelling work was performed on this data set. The obtained solubility data were used only 
as a guideline to the dissolution point at high temperatures. 
6.3 Cooling Crystallisations 
6.3.1 Rapid Cooling Crystallisation 
In order to determine the impact that the solvent may have on the crystal form of the 
material the four ILs were taken forward for further scoping studies. Using the solubility 
data obtained at 358.15 K, a flufenamic acid solution was dissolved at this concentration by 
taking the solution to 363.15 K to ensure full dissolution. The resulting solutions were then 
crash cooled to room temperature at a rate of 10 K.min-1. No XRD data are reported for 
these samples as the resultant crystals produced poor x-ray diffraction patterns due to 
excess IL on the surface of the crystals.  
The samples were analysed by optical and SEM as shown in Table 6.3. Samples from 
[bmim][PF6] and [bmim][NTf2] produced yellow needle-like crystals indicative of form III 
while samples from [hmim][PF6] and [bmim][BF4] produced white plate-like crystals 
indicative for form I (López-Mejías et al, 2012). 
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Table 6.3: Microscopy Images of Flufenamic Acid 
6.3.2 Primary and Secondary Nucleated Systems 
The ILs [bmim][PF6] and [bmim][BF4] were taken forward for further studies due to the 
higher achievable solubility in these solvents. To establish if a controlled crystallisation could 
be conducted using these solvents two ILs that gave differing polymorphic forms during the 
crystallisation were selected for further investigation. A further cooling crystallisation was 
conducted at a slower cooling rate at a concentration equal to the concentration at 358 K. 
The nucleation point from this crystallisation was used to determine the point at which 
spontaneous crystallisation would occur. Using this knowledge a second seeded 
crystallisation was then performed seeding at 5 K above the point of nucleation from the 
Ionic 
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Optical Microscopy Scanning Electron Microscopy 
50X Magnification 100X Magnification 100X Magnification 250X Magnification 
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primary nucleated system. A summary of the form as determined by XRD is shown in Table 
6.4 with the raw data in Appendix 7. 
Crystallisation XRD 
[bmim][PF6] 
(non-seeded) 
Mixture of Form I and III 
[bmim][PF6] 
(seeded with form III) 
Form III 
[bmim][BF4] 
(non-seed) 
Form I 
[bmim][BF4] 
(seeded with form I) 
Form I 
Table 6.4: Summary of Flufenamic Acid Form Results  
A mixture of forms was produced from the non-seeded [bmim][PF6] experiment, though 
when seeded with form III a pure sample of form III was produced. The particle habit 
matched the findings from the XRD as shown in Table 6.5. 
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Table 6.5: OM and SEM Images of Crystallised Flufenamic Acid 
Typical methods used to produce flufenamic acid include crystallisation from hot toluene (Li 
et al, 2010) and hot mixed xylene (Delaney et al, 2014) to produce form I; the same authors 
were also able to produce form III from methanol. In a similar light López-Mejías et al (2012) 
used polymers as heteronulcei to produce a range of forms from ethanol. The short scoping 
work applied here shows that, as with conventional solvents, in some cases metastable 
forms of flufenamic acid can be obtained by choosing a solvent that has different hydrogen 
bonding propensity. 
Ionic 
Liquid 
Optical Microscopy Scanning Electron Microscopy 
50X Magnification 100X Magnification 100X Magnification 250X Magnification 
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6.4 Summary 
The scoping work here has shown that different forms of flufenamic acid can be isolated 
though changing the IL used and the method of crystallisation. The polymorphs identified 
here are similar to those isolated at similar conditions in the literature. ILs do offer the 
opportunity to work at temperatures beyond those possible with organic solvents. 
Therefore for future work it would be prudent to investigate extremes of temperature to try 
and identify any new polymorphs, though this may lead to experimental difficulties due to 
the formation of gel-like systems. 
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CHAPTER 7:  PROBLEMS AND SOLUTIONS 
7.1 Introduction 
The purpose of this chapter is to document some of the issues encountered during the 
development of solubility and crystallisation practical work. They include well known 
problems that were anticipated at the outset of the work but also some problems that were 
encountered during development. 
The work focussed on two main areas; methods to measure solubility and improving the 
filtration time. Hopefully future research will be able to build on any lessons learnt in this 
work so that similar problems are easily resolved. 
7.2 Solubility Determination Methods 
The first method commonly used with organic or aqueous-based systems is a gravimetric 
method where a saturated solution is weighed before evaporating off the solvent and 
weighing the remaining solid. This method obviously is not possible given the negligible 
vapour pressure of ILs. The choice of method available is limited to those that rely either on 
confirmation of dissolution of a known weight of API into a known volume or weight of 
solvent or by spectroscopic methods.  
While confirmation of dissolution can provide a gross estimation of solubility, significant 
errors may be encountered when working with ILs in this manner. Particularly at low 
temperatures the viscosity of the ILs can increase significantly especially as solute is 
dissolved. Efficient mixing of the viscous slurries can prove challenging. If the dissolution 
point is being detected by a probe, care must be taken to ensure the proper point of 
dissolution is correctly recorded. If the assessment is conducted by eye, significant human 
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error may also occur. Many of the ILs are coloured making point of dissolution more difficult 
to determine. 
This leaves spectroscopic methods such as the one used in this thesis. The most common 
method would be detection via Ultra Violet (UV) spectroscopy. However for this to be 
possible then the solute must have a chromophore. Other methods such as Charged Aerosol 
Detectors (CAD) are unlikely to be compatible with ILs as are likely to interfere with 
detection of the solute.  
From a practical point of view there are also other factors that need to be considered. ILs 
can operate in temperature windows far outside those for conventional solvents. When 
developing data for process development, researchers have never had to operate outside 
these tight temperature ranges and as such much of the equipment used is not capable of 
exploiting this full range. Also it can be difficult to deal accurately with slurry mixtures that 
are at the extremes of temperature, not just from a method accuracy view point but also 
from the point of view of the safety of the operator. Another perhaps overlooked point is 
that if using weight to determine the solubility then steps need to be taken to avoid 
contaminating gloves when handling vials. As the IL is non-volatile any contamination could 
be passed onto outside of the vial and impact the accuracy of any weight measurements. 
 In order to be able to exploit the range of temperatures that ILs can operate at, using 
probes to give an online assessment of the solution concentration may be a viable option, 
so reducing the exposure to the operator and the error associated with sampling at 
extremes of temperature.  Although the online readings will vary with changes in 
temperature, calibration curves can be determined to account for this. 
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7.3 Filtration 
The high viscosity of ILs could result in a number of manufacturing problems. For example 
an important practical consideration when using ILs as pharmaceutical solvents is whether 
the product can be efficiently separated from the crystallisation liquor. In most 
pharmaceutical processes this is achieved using simple filtration through a mesh to leave a 
cake of material on the filter bed. The cake is then commonly washed with clean solvent 
before drying to remove any excess solvent. Working with ILs this provides a problem as all 
residual will need to be removed prior to any drying process. This could be achieved by 
displacing the ILs using a miscible solvent that is a poor solvent for the solute being 
crystallised.  
7.3.1 Anti-solvent Crystallisation to Improve Filtration 
To assess the issue a crystallisation of paracetamol was completed in the IL 
[bmim][C8H17OSO3] which was found to be highly viscous when conducting the solubility 
studies in previous chapters. Three crystallisations were completed: a non-seeded cooling 
crystallisation, a seed crystallisation and an anti-solvent crystallisation. The aim was to 
determine the filtration performance for a highly viscous IL and the impact of adding a 
second solvent to reduce the viscosity.  
To assess the filtration performance, a modified Darcy’s equation was used which assumes a 
constant pressure cake filtration process (Ghosh, 2006). The constant pressure equation to 
used here to describe filtration performance is derived from Darcy’s Law is shown below. 
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where,    is the average cake resistance in m.kg-1, A is the filtration area in m2, c is the solids 
concentration kg.m-3, ΔP is the pressure differential in Pa (Pa), R is the resistance of the filter 
medium in m-1, t is the elapsed filtration time in s, μ is the dynamic viscosity of the filtrate 
and V is the volume in m3. 
To make the comparison it was assumed that the filter resistance was negligible and the 
temperature was 293.15 K (to which all experiments had been cooled). Dynamic viscosity 
for [bmim][ C8H17OSO3] was taken from data in the literature (Wasserscheid and Hal, 2002). 
For the anti-solvent system, the presence of [bmim][ C8H17OSO3] was neglected because of 
its small volume and data for pure dichloromethane (DCM) was used (Yaws 2012). The 
results are shown in Table 7.1 
Crystallisation Type Cake Resistance m.Kg-1 
Cooling (non-seed) 3.9E+12 
Cooling Seeded 1.4E+12 
Anti-Solvent 6.8E+09 
Table 7.1: Measured cake resistance for [bmim][ C8H17OSO3]  Paracetamol Crystallisations 
This cake resistance value can be plotted to give an indication in order to generalise the 
filtration performance as shown in Figure 7.1. The data obtained here demonstrate the  
poor filtration of the highly viscous IL. Employing seeding to increase the particle size 
improved the filtration but it can still be considered to be slow. The use of an anti-solvent to 
dilute the system improved the filtration significantly as this sample performed well. 
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Figure 7.1: Calculated Cake Resistance for [bmim][ C8H17OSO3]  
For comparison to previously crystallised material the output was analysed in-line with the 
previous paracetamol samples. The form of the material was consistent with the previously 
crystallised samples, form I. The images for the particles are shown in Table 7.2. 
Table 7.2: Paracetamol Images from [bmim][ C8H17OSO3] Crystallisations 
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The images show that particle habit of paracetamol can be modified through changing the 
anion used for crystallisation. From [bmim][ C8H17OSO3] primary nucleation produced a 
columnar particle habit with primary particle size in the region of 100 µm by 20 µm in size. 
The seeded samples produced much larger particles with a distinctive cube or cuboid shape 
with primary particles in the region of 100 µm by 70 µm by 70 µm. Although crystallisation 
was initiated prior to the addition of the DCM the addition of the anti-solvent did impact the 
particle habit and size. The particle shape is less well defined and in general the particle size 
is smaller with typical particles around by 50 µm by 10 µm. 
The experiment shows one potential solution to improving the filtration rate of highly 
viscous ILs. This solution also means that ILs where the solubility of the solute was deemed 
to be too high to develop a commercially viable process could be considered if combined 
with a suitable anti-solvent to ensure a satisfactory yield. 
The disadvantage of this approach is that the introduction of anti-solvent means that any 
possible benefit from a green chemistry aspect is lost and this approach also restricts the 
temperatures at which the material can be isolated. Also recycling of ILs may be required to 
make any process commercially viable and addition of a second solvent would require 
additional separation process to re-purify the IL. 
7.3.2 Anti-solvent Crystallisation to Improve Filtration 
A possible solution to the above disadvantages would be to use a CO2 as an anti-solvent. 
Some scoping experiments were carried out to determine the feasibility of this approach by 
completing some small scale experiments using scCO2 as anti-solvent. Crystals were formed, 
Figure 7.2, that show that this approach may be viable and worthy of future investigation. 
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Figure 7.2: SCF crystallised Paracetamol from [hmim][PF6] 
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CHAPTER 8: CONCLUSIONS AND FURTHER WORK 
8.1 Conclusions 
Ionic liquids have unique properties that, when compared to organic solvent, have been 
investigated by various industries a means to improve chemical processes. To date, little 
work has been conducted on their potential use in the pharmaceutical industry. The work 
that has been carried out had mainly focussed on either their use as drug delivery vehicles 
or as an Active Pharmaceutical Ingredients (APIs). Assessing their applicability as media to 
carry out crystallisations has not been extensively reported particularly for small molecules 
and it was this gap that the thesis looked to address. 
To investigate this a set of criteria to select suitable ILs for this work is provided. Using these 
ILs and model API compounds a study was conducted to try and help address this current 
gap in the literature. 
Methodology to determine the equilibrium solubility of API in ILs was established and 
successfully used to measure the solubility of paracetamol and ibuprofen in the ILs 
[bmim][PF6] and [hmim][PF6]. These ILs were found to be good solvents for both 
paracetamol and ibuprofen and the data have now been published for the first time (Smith 
et al, 2011).  
In the literature it is debated as to whether, like conventional solvents, polarity could be 
used as a measure to describe the solvation capability of a solvent. The data reported here 
show that, when compared to water, the ILs follow the expected trend when considering 
their relative polarity against water.  
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Further to this it was shown, using the Dual parameter and Buchowski equations, that good 
correlations to the experimental data were obtained for the systems studied. Such data fits 
may aid the selection of an IL by allowing fewer data points to be generated when screening 
an IL for a given process. 
Building on these data the Meta-Stable Zone Width (MSZW) for both paracetamol and 
ibuprofen in [bmim][PF6] and [hmim][PF6] were determined. A feature of the systems 
studied was that large supersaturations could be generated increasing the potential risk of 
meta-stable forms crystallising if left uncontrolled. A series of cooling crystallisations 
designed to determine the impact of supersaturation both with and without seeding were 
carried out to determine the impact on the physical form.  
Despite the range of supersaturations investigated no meta-stable forms of either 
paracetamol or ibuprofen were obtained even at fast cooling rates. However it was found 
that the particle habit of paracetamol could be altered by changing either the concentration 
or the length of the alkyl chain. Particularly for samples that were allowed to form through 
spontaneous nucleation. The wide MSZW obtained meant that seeding could be used be 
used as a possible strategy to facilitate crystal growth. Less variation in the particle habit 
was observed for the seeded samples, but it shows seeding can be successfully in employed 
to grow crystals in ILs to produce much larger particles. 
Using the criteria established at the start of the thesis the crystallisation work was extended 
to a homologous series of ILs with the aim of determining the effect that the anion had on 
the crystallisation of paracetamol. A screening method to assess potential ILs as 
crystallisation solvents is described and could be used as a basis for future screening work. 
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Interestingly it was found that further particle habits of paracetamol were produced 
including cubic shaped particles that have not been reported before whilst remaining as the 
most stable form.  This is potentially an exciting finding as manipulation of the physical habit 
could provide advantages for the manufacturability of API to help avoid common issues such 
as poor powder flow. 
For the crystallisation studies involving ibuprofen the material formed was typical of that 
reported for conventional organic solvents. Highlighting that ILs may not be a platform for 
manipulation of all APIs, but will be dependent on whether the IL can sufficiently interact 
with the API to influence the relative growth rates of the crystal faces. 
The screening method established during the paracetamol work was then successfully used 
to assess the crystallisation of the highly polymorphic flufenamic acid. Through this screen 
two different polymorphs of flufenamic acid were produced by changing the anion of the IL. 
During these investigations the practical problems encountered with these solvent/solute 
media were reported and where possible practical solutions investigated. The majority of 
issues encountered relate to either the ability to conduct analysis on the IL-API system or 
the ability to separate the IL from the API after crystallisation. 
At the outset of the thesis the main aim was to investigate whether ionic liquids could be 
viable media to crystallise API and given the highly functional nature of these materials if 
they offer a new route to manipulation of the physical form. It has been shown here using 
well characterised ionic liquids and APIs that crystallisations can successfully be carried out 
in these media and the physical form of the API can be manipulated, such as  crystal habit 
for paracetamol and polymorphic form of flufenamic acid. 
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However, further understanding is required to determine the interaction between IL and 
solute if ILs are ever to fulfil their potential as designer solvents. From this work there are a 
number of areas that would be suitable for further investigation these are outlined in the 
section below. 
8.2 Suggested Further Work 
It would be beneficial to develop the selection criteria used here further to include more 
physical property factors, such as viscosity, to ensure that a more targeted approach could 
be taken in the selection of a suitable IL and to ensure that potential manufacturability 
issues such as filtration can be avoided. Also, methods for providing an efficient and 
complete removal of the IL from isolated solid need to be explored. 
One of the major findings from this work was the manipulation of the particle habit of 
paracetamol which, in some cases, produced unique habits. By indexing crystals formed 
from these systems it will be possible to determine what faces are impacted during crystal 
growth and establish which anions are responsible for altering particle habit and the crystal 
faces they interact with. 
This work only looked at a small sub-set of possible ILs by investigating modest changes to 
the alkyl side chain and the impact of changing the anion whilst retaining the same [bmim]+ 
cation. It would therefore be interesting to carry out a similar study to determine the impact 
of the cation has on crystallisation by using similar methodology employed in this work.                                          
It was shown here that at least two polymorphs of flufenamic acid can be isolated from ILs. 
It may be possible to isolate further polymorphs through operating at temperatures outside 
the normal range of organic solvents. If successful, such methodology could be expanded to 
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determine if this property should be considered by the pharmaceutical industry when 
screening for all possible polymorphs of an API. 
One current disadvantage to the use of ILs in the pharmaceutical industry is the high cost 
when compared to commonly used organic solvent. Given the lack of volatility in ILs it may 
be feasible to re-cycle ILs and thus a cost model should be established to determine the 
economic viability of ILs in commercial use. 
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Appendix 1: UV and Corresponding Solubility Data for Paracetamol in 
[bmim][PF6], [hmim][PF6] and Water 
 
Solubility of Paracetamol [bmim][PF6] 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 0.5836 7.010 0.5669 6.803 0.5870 7.051   
 0.5840 7.014 0.5650 6.778 0.5870 7.051   
 0.5832 7.004 0.5653 6.783 0.5860 7.040   
  0.5836 7.009 0.5657 6.788 0.5867 7.047 0.579 ± 0.011 6.95 ± 0.14 
308.15 K 
 0.8413 10.205 0.8777 10.656 0.7628 9.232   
 0.8439 10.237 0.8798 10.682 0.7625 9.228   
 0.8407 10.198 0.8829 10.720 0.7677 9.292   
  0.8420 10.213 0.8801 10.686 0.7644 9.251 0.829 ± 0.059 10.05 ± 0.73 
318.15 K 
 0.8591 10.425 1.0219 12.444 0.8406 10.196   
 0.8582 10.414 1.0241 12.471 0.8360 10.139   
 0.8549 10.374 1.0243 12.474 0.8400 10.189   
  0.8574 10.404 1.0234 12.463 0.8389 10.175 0.907 ± 0.102 11.01 ± 1.26 
328.15 K 
 1.2921 15.794 1.2711 15.534 1.2806 15.652   
 1.2848 15.704 1.2718 15.543 1.2826 15.677   
 1.2922 15.796 1.2739 15.569 1.2879 15.742   
  1.2897 15.765 1.2723 15.549 1.2837 15.690 1.282 ± 0.009 15.67 ± 0.11 
338.15 K 
 1.8928 23.243 1.8741 23.011 1.8860 23.159   
 1.8694 22.953 1.8620 22.861 1.8980 23.307   
 1.8912 23.223 1.8448 22.648 1.9039 23.380   
  1.8845 23.139 1.8603 22.840 1.8960 23.282 1.880 ± 0.018 23.09 ± 0.23 
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Solubility of Paracetamol [hmim][PF6] 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 1.0586 14.137 0.9240 12.287 0.9921 13.222   
 1.0529 14.059 0.9010 11.971 0.9769 13.014   
 1.1243 15.040 0.9032 12.001 0.9866 13.147   
  1.0786 14.412 0.9094 12.086 0.9852 13.128 0.991 ± 0.085 13.21 ± 1.17 
308.15 K 
 1.0969 14.663 1.1535 15.441 1.1324 15.151   
 1.1105 14.850 1.1359 15.199 1.1431 15.298   
 1.0985 14.685 1.1528 15.432 1.2153 16.291   
  1.1020 14.733 1.1474 15.357 1.1636 15.580 1.138 ± 0.032 15.22 ± 0.44 
318.15 K 
 1.7519 23.665 1.5291 20.603 1.5215 20.499   
 1.5533 20.936 1.4566 19.607 1.4878 20.036   
 1.6814 22.696 1.5215 20.499 1.4233 19.149   
  1.6622 22.433 1.5024 20.236 1.4775 19.895 1.547 ± 0.100 20.86 ± 1.38 
328.15 K 
 1.9636 26.575 2.0446 27.688 2.0140 27.268   
 1.9802 26.803 1.7765 24.004 1.9426 26.286   
 2.0153 27.286 1.8713 25.306 1.7699 23.913   
  1.9864 26.888 1.8975 25.666 1.9088 25.822 1.931 ± 0.048 26.13 ± 0.67 
338.15 K 
 2.0919 28.338 2.6430 35.913 2.2619 30.675   
 2.7377 37.214 2.3552 31.957 1.6741 22.596   
 2.3482 31.861 2.0428 27.663 2.0230 27.391   
  2.3926 32.471 2.3470 31.844 1.9863 26.887 2.242 ± 0.223 30.40 ± 3.06 
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Solubility of Paracetamol Water 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 1.1484 19.467 1.1100 18.809 1.1316 19.179   
 1.1479 19.458 1.1129 18.858 1.1328 19.199   
 1.1458 19.422 1.1116 18.836 1.1330 19.203   
  1.1474 19.449 1.1115 18.834 1.1325 19.194 1.130 ± 0.018 19.16 ± 0.31 
308.15 K 
 1.4496 24.628 1.4993 25.479 1.5496 26.341   
 1.4445 24.540 1.4998 25.488 1.5504 26.355   
 1.4433 24.520 1.4932 25.375 1.5468 26.293   
  1.4458 24.562 1.4974 25.447 1.5489 26.330 1.497 ± 0.052 25.42 ± 0.88 
318.15 K 
 2.0890 35.583 1.9437 33.094 2.0178 34.363   
 2.0829 35.479 1.9557 33.299 2.0306 34.583   
 2.1095 35.935 1.9516 33.229 2.0262 34.507   
  2.0938 35.666 1.9503 33.207 2.0249 34.485 2.023 ± 0.072 34.45 ± 1.23 
328.15 K 
 1.4636 49.247 1.5803 53.207 1.5634 52.634   
 1.4610 49.159 1.5692 52.831 1.5615 52.569   
 1.4562 48.996 1.5766 53.082 1.5635 52.637   
  1.4603 49.134 1.5754 53.040 1.5628 52.614 1.533 ± 0.063 51.60 ± 2.14 
338.15 K 
 1.9296 65.060 2.0389 68.769 1.9755 66.618   
 1.9149 64.561 2.0322 68.542 1.9567 65.980   
 1.9299 65.070 2.0260 68.331 1.9584 66.038   
  1.9248 64.897 2.0324 68.547 1.9635 66.212 1.974 ± 0.055 66.55 ± 1.85 
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Appendix 2: X-Ray Diffraction Patterns for Paracetamol 
 
 
 
 
 
 
 
 
 
 
Paracetamol Monoclinic Form I X-Ray Pattern 
 
 
 
 
 
 
 
 
 
 
Paracetamol Orthorhombic Form II X-Ray Pattern 
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Paracetamol [bmim][PF6] (non-seeded) 
mg.mL-1 XRD Trace 
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54.85 
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Paracetamol [hmim][PF6] (non-seeded) 
mg.mL-1 XRD Trace 
15.73 
 
30.21 
 
69.06 
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Paracetamol [bmim][PF6] (seeded) 
mg.mL-1 XRD Trace 
38.1 
 
47.4 
 
57.0 
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Paracetamol [hmim][PF6] (seeded) 
mg.mL-1 XRD Trace 
35.0 
 
49.0 
 
63.0 
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Paracetamol [bmim][BF4] Non-Seeded 
 
 
 
 
Paracetamol [bmim][BF4] Seeded 
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Paracetamol [bmim][NTf2] (non-seeded) 
 
 
 
Paracetamol [bmim][NTf2] (seeded) 
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Appendix 3: Paracetamol Sizing Data 
[bmim][PF6] 45 mg.mL
-1 
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[bmim][PF6] 55 mg.mL
-1 
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[bmim][PF6] 75 mg.mL
-1 
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[hmim][PF6] 16 mg.mL
-1 
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[hmim][PF6] 30 mg.mL
-1 
 
158 
 
[hmim][PF6] 69 mg.mL
-1 
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[bmim][PF6] 38 mg.mL
-1 
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[bmim][PF6] 47 mg.mL
-1 
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[bmim][PF6] 57 mg.mL
-1 
 
162 
 
[hmim][PF6] 35 mg.mL
-1 
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[hmim][PF6] 49 mg.mL
-1 
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[hmim][PF6] 63 mg.mL
-1 
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Appendix 4: UV and Corresponding Solubility Data for Ibuprofen in 
[bmim][PF6], [hmim][PF6] and Water 
 
 
 
 
 
 
 
 
 
Solubility of Ibuprofen [bmim][PF6] 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 0.6984 12.036 0.7225 12.496 0.6996 12.059   
 0.6961 11.992 0.7209 12.464 0.6969 12.006   
 0.6979 12.026 0.7232 12.509 0.6961 11.992   
  0.6975 12.018 0.7222 12.490 0.6976 12.019 0.706 ± 0.014 12.18 ± 0.27 
308.15 K 
 1.1586 20.816 1.1196 20.072 1.1111 19.910   
 1.1618 20.877 1.1184 20.049 1.1116 19.919   
 1.1625 20.890 1.1230 20.137 1.1106 19.900   
  1.1610 20.861 1.1203 20.086 1.1111 19.910 1.131 ± 0.027 20.27 ± 0.48 
318.15 K 
 1.6351 29.908 1.7479 32.060 1.7723 32.525   
 1.6445 30.087 1.7387 31.884 1.7692 32.466   
 1.6518 30.226 1.7424 31.955 1.7780 32.634   
  1.6438 30.074 1.7430 31.966 1.7732 32.542 1.720 ± 0.068 31.53 ± 1.29 
328.15 K 
 2.6332 35.721 2.6530 36.001 2.6016 35.272   
 2.7533 37.424 2.6328 35.715 2.7151 36.882   
 2.7451 37.308 2.7561 37.464 2.6701 36.244   
  2.7105 36.817 2.6806 36.393 2.6623 36.133 2.685 ± 0.024 36.45 ± 0.35 
338.15 K 
 2.9031 57.125 2.7834 54.673 2.8436 55.907   
 2.8040 55.095 2.8825 56.703 2.9839 58.781   
 2.9421 57.924 2.9774 58.647 2.8674 56.394   
  2.8831 56.715 2.8811 56.675 2.8983 57.027 2.888 ± 0.009 56.81 ± 0.19 
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Solubility of Ibuprofen [hmim][PF6] 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 1.1889 24.963 1.3726 28.975 1.2135 25.500   
 1.1949 25.094 1.3521 28.527 1.2137 25.504   
 1.1981 25.164 1.3669 28.850 1.1851 24.880   
  1.1940 25.073 1.3639 28.784 1.2041 25.295 1.254 ± 0.095 26.38 ± 2.08 
308.15 K 
 1.6187 34.349 1.7179 36.516 1.7719 37.695   
 1.6312 34.622 1.8077 38.477 1.8282 38.925   
 1.6440 34.902 1.7524 37.269 1.9703 42.028   
  1.6313 34.624 1.7593 37.421 1.8568 39.549 1.749 ± 0.113 37.20 ± 2.47 
318.15 K 
 2.2271 52.836 1.9970 47.403 2.1606 51.266   
 2.1217 50.347 2.0132 47.786 2.2754 53.976   
 2.2624 53.669 2.0162 47.856 2.1801 51.726   
  2.2037 52.284 2.0088 47.682 2.2054 52.323 2.139 ± 0.113 50.76 ± 2.67 
328.15 K 
 2.0340 66.845 1.9737 64.873 1.9816 65.131   
 2.0561 67.567 2.0020 65.798 2.0042 65.870   
 2.0378 66.969 1.9756 64.935 1.9760 64.948   
  2.0426 67.127 1.9838 65.202 1.9873 65.317 2.005 ± 0.003 65.88 ± 1.08 
338.15 K 
 1.4135 124.158 1.3190 115.920 1.3697 120.340   
 1.4239 125.065 1.3257 116.504 1.3667 120.078   
 1.4182 124.568 1.3257 116.504 1.3724 120.575   
  1.4185 124.597 1.3235 116.309 1.3696 120.331 1.371 ± 0.048 120.41 ± 4.15 
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Solubility of Ibuprofen Water 
298.15 K 
 Sample 1 Sample 2 Sample 3  abs                   
 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 abs mg.mL-1 
 0.2217  0.128 0.2103  0.122 0.2075 0.121   
 0.2218 0.129 0.2112  0.123 0.2076  0.121   
 0.2220 0.129 0.2101  0.122 0.2074 0.121   
  0.2218 0.129 0.2105 0.122 0.2075 0.121 0.213 ± 0.008 0.124 ± 0.004 
308.15 K 
 0.2829 0.162 0.3042 0.174 0.3522 0.201   
 0.2829 0.162 0.3042 0.174 0.3524 0.201   
 0.2828 0.162 0.3036 0.174 0.3522 0.201   
  0.2829 0.162 0.3040 0.174 0.3523 0.201 0.313 ± 0.036 0.179 ± 0.020 
318.15 K 
 0.3570  0.203 0.4758  0.269 0.6351  0.357   
 0.3558 0.203 0.4755  0.269 0.6345 0.357   
 0.3563 0.203 0.4760 0.269 0.6351  0.357   
  0.3564  0.203 0.4758 0.269 0.6349 0.357 0.489 ± 0.140 0.276 ± 0.077 
328.15 K 
 0.5533  0.312 0.6468  0.363 0.8037 0.450   
 0.5551 0.313 0.6468 0.363 0.8044 0.451   
 0.5553 0.313 0.6484 0.364 0.8054  0.451   
  0.5546 0.312 0.6473 0.364 0.8045 0.451 0.669 ± 0.126 0.376 ± 0.070 
338.15 K 
 0.8284 0.464 1.1082  0.618 0.8709 0.487   
 0.8284  0.464 1.0930  0.610 0.8714 0.488   
 0.8303 0.465 1.1103 0.620 0.8717 0.488   
  0.8290 0.464 1.1038  0.616 0.8713 0.487 0.935 ± 0.148 0.523 ± 0.082 
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Appendix 5: X-Ray Diffraction Patterns for Ibuprofen 
 
 
 
 
 
 
 
 
 
 
 
 
Ibuprofen Form I X-Ray Pattern 
 
 
 
 
 
 
 
 
 
 
 
Ibuprofen Form II X-Ray Pattern 
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Ibuprofen [bmim][PF6] (non-seeded) 
mg.mL-1 XRD Trace 
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Ibuprofen[hmim][PF6] (non-seeded) 
mg.mL-1 XRD Trace 
79 
 
120 
 
155 
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Ibuprofen [bmim][PF6] (seeded) 
mg.mL-1 XRD Trace 
61 
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84 
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Ibuprofen [hmim][PF6] (seeded) 
mg.mL-1 XRD Trace 
113 
 
136 
 
158 
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Appendix 6: Ibuprofen Sizing Data 
[bmim][PF6] 28 mg.mL
-1 
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[bmim][PF6] 57 mg.mL
-1 
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[bmim][PF6] 83 mg.mL
-1 
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[hmim][PF6] 79 mg.mL
-1 
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[hmim][PF6] 120 mg.mL
-1 
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[hmim][PF6] 155 mg.mL
-1 
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[bmim][PF6] 61 mg.mL
-1 
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[bmim][PF6] 72 mg.mL
-1 
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[bmim][PF6] 84 mg.mL
-1 
 
182 
 
[hmim][PF6] 113 mg.mL
-1 
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[hmim][PF6] 136 mg.mL
-1 
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[hmim][PF6] 158 mg.mL
-1 
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Appendix 7: X-Ray Diffraction Patterns for Flufenamic Acid 
Reference XRD Patterns 
Form XRD Trace 
I 
 
II 
 
III 
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